var title_f31_12_31936="ECG junctional premature beat";
var content_f31_12_31936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) strips showing junctional premature beats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 547px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIjAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivF/wBoXU9Vv5tI8IeGn1VdQuo5tQuW0o/v44Y1Kx55HytKyA89FNAHtFFcb8IPE7eLvh5o+p3BYXwi+z3itwy3EfySZHbJGcehFdlQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO+NdXu9MsreLT4Ltri7kMX2mCzkuRargkyMiKxJHRQRgsRnjNea2HirWNR8I2mqtqV5HdWXhnTdSRdvlfa7qV5Fl3qVG4ExKBjjEuV6qa9srzn4j+KvAXgK20x/EtlaiS0QDToItPEjRBcYER27UxtGOVA2j0oASLVtRPiyGY305EmvyaU1luHliBbR5BhcZ3ZUSbuuDjpir/jzxXqWgz6l/Z8Fm8WnaRLrE3nhi0qxk5iXBG0kD7xzj+6a8+8HfGnwv4li8Y+JYvD9nYX+i2fnQTXLxLdXo2SHYGAyP9WowC33hUngz49+BPGtwLLWtNfT9SvIjaPFdWwuI5o2zmLeoJKnnIZQKAOy1LxV4jtLjULGOztbi5tLmMSz21vJKIoHhLg+QHDyEMAh2sOGDbeCK7bRL+PVNGsNQgljmhu7eOdJIgQjqyhgVzzg54zzXNfETSbK90+1VrSz8281C1jkmks4ZnwW2k4kRhnaWUEg4BNS+IbPUNF8PX19Za7qB+xW7TJC0Nt5e1Bu24EQOMAjgjg8c4NAHW0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVBfwyXFjcwwTtbzSRsiTKATGxBAYZ7g81w3gvxFqPiq7JjuFtzYaaLe9UIGVdRZirqRwT5XlHjIyJR+AB6BSAgkgEEg4PtXOfDq9vNR8GabdalcG5vHDiSYqF3kOwzgcDpUmpaTewaw+qeH2so7i4jEV3FcIQk237j5XncuSO+QQP4RQB0FFc/FB4ocyJPqGjRqPuzRWUhZwf9gy4Qjp1bPXjpWFp0Wo3enaXok+rX0jm7vftl4r7J5oYpXUDcMbMl4uVxgDAx2AOxbVNPXVV0xr22GovGZVtTKvmlP723Oce9XKwZ/DNommxW+l/6HcQzrdRXDAyv5o4LOWO59ykoSWyVYjIpbi38SrKr2+oaVIp+UxvZyIAP7wIkJJHpwD0yOtAG7Wdrus2eiWi3F+8gV3EcccMTSySMedqIgLMcAk4HABJ4BNY11eavpetrLqV/aTWC6bcztFDamEeZG0RDEl2P3WYY4/Hta8KaIlpZ21/f7rrW5oVa4u5iWfcwBZUznYmeiLgfU80AbNjdwX9lb3lpIJba4jWWJx0ZWGQfyNT1zEnhm8tXkbQtdvLKLzjcJZPHHLbhycsvK7wjEnKhxjPy46VBrlz4m0y2sbqS90p4ftttFcpHZurGOSZI2Cs0pAwHzkj+HpzwAddVXTdQstUtFutMvLe8tWJCzW8qyISDggMCRwa502J8U6hfG/vJzo9pc+QljFhI5ygUsZWHzMN5YbAQpC/MGq/Lot1a6jcXWhXdpZC5RBNDLaGVGdRgOArphtuFPXIVOmOQDdornbW38VKXinv9IKITsuGtZHeUHpuQOgQjgcE59qwNJ1HVNctNC0q91GSC7mS9a+uLQLHJJ9mmWFlXg7AzOCSuCMcEZzQB2UWs6bLrE2kxX9q+pwxiWS1WUGVUPcr1xyPzHqKv1gT+F7KOxs4tJSKyuLKb7RbzlPMIkIw5fJDPvUsGJbJznOeaaLHxMJm/4nmnGJ/mP/Etbch9F/e4x067j155GADoapXmradZXtrZ3l/aW93dkrbwSzKrzEdlUnLfhXHNLrdtFrGntq0st7catbwx3QjVTBDJFDu8tDkDAEhGc8kk56HfHhLS00i7sY1mD3SjzbxpTJcs4OVfzHySythlzwCBgY4oAx/inb+MLjT9PHgaaGK4W7hNx5r7VKedEeykkYDbsEfJvGGJUV12middOtResTciJBKSQSXwN3IAB5z0AHsK5PXB4j0u20u5uddglijv7WCZYLERGdJZki+cs7D+MH5AvI9OKk07TF8UTXd/rc1xPZR3k9vBpxYLbhYZGi3OoH7wsUZsOSoyMAYzQB2CsrqGQhlPIIOQaWuct9BvNJuLn/hHbuztLGd/NNnPatIkb4AYx7XXYpxkrg/Nk9zUsg8TiJjG+jNKBkApKoY+mcnGfXnHoaAN6iuP1bVfE2nWEN/eQ6RbQi7t45reNpLhhE8yRsRJ8gBCtu+6QMY5604W1z4pvdRFzqE8GjW101qtra7U+1BFXf5r4LY3712oV4XnOcUAddzzmiuXXQ77Rb24fwqumwWV2VaW0mRkjhkAwZECDncoUFeBlQc5JzS8Tx+MJ/CmrSw6jpekXYtZGjFrA908bBSQRK7ICTjvHxnv1oA7WsiK90PxIuoaektjqSW7+Td27bZQp54ZTx2I+oI7Gsp7dfE+rNFdXdwdMt7SCRrWGUxpLJIWYiQrhmAUJ8udpDHIOa0b3QyktlcaHLb6dcWkRt0X7OHiaE4+QoCvAIBGCMc9iQQDN0n4c+FNHtNdtdJ0aCzttbi8i+ihZlSVNrrgDOF4dvu461d8KeDPDnhK38nw5o1nYDGC8Uf7xh/tOcs34k0Q2XiSOR1fWrCWJyW3vYEOmf4VAkA2jtnJ7HPWuQuJtbtbTWdH0/Vbi41d9diigubtguQbeK5ZPlXCoQsicKcAk4J5IB1/jAM40VFA+bU4CeCeAS3b/dp/j0E+BfEYBwTptzg/9smqnJF4j1HUdK+36bpVra29x9olkg1F5n4RxgK0Cg5LDuOK6HUbSPUNPurOYkRXETwvjrhgQf50AWKK5a2n8YW1tHC+kaJcNGoTzhqsqeZgY3Ffs5259MnHqav6Td6/NetHqukWFpbAHE0GoNOSew2mJOPfNAG1RRRQAUUUUAFFFFABRRRQAUUUUAFU00vT0gvIUsbVYb1me5jEKhZ2YYYuMfMSAASc5Aq5RQBS0jSdO0a1Nto+n2lhbli5itYViQscAnCgDPA59qu0UUAFcN4acN41vIR1tmvs/wDbSS3YfyNdzXnvgt1b4p+OoSFD24tDxzxIjN+H3RxQB6FRRRQBw/xQkMNrA6khntr2FSBnlrdiP1UV3Fef/F5njHhExj/W67DbM2cbVkjkX9SQPxr0CgArA8eN5fhLUZgMmBFn6/3GD/8Astb9Y3jTA8Ha6SQALCfk9v3bUAV/Ain/AIR9pSxcXF7eXCse6yXMrr/46wroaxPBCbPB+i853WkT5/3lB/rW1kbiuRkDOKAFrgPA8Cf8Jbqajj7ELohen/HxfTux/wDIQrvx0561wngfP/CeeOEO7NvLbw4P+0JJhj8JxQB3dFFFAHC3s5X4nQW247Wa1l24Pe3vxn/yGPyruq4C8df+F020BzufTYZx06Rm7U/+jh+dd/QBg+OYy/hmdhwYpYJ/+/cyP/7LTPh9sbwVo80bBlubdbrcO/m/vM/+PU/x84i8DeIZGxiPT7h+mekbH+lL4BgFr4F8OW6jAi022QfhEooA3aKKKAOd+IcbSeDNUKDLRIswBGfuMH/9lp3gRT/wjiSkkm4ubq5+nmXEkmPw3Yp3j6TyfAviOX/nnp1y/wCUTGn+B+fBmhMRgvYwuR7sgJ6+5oA26bIiyRsjjKsCCPanUUAcF8H5zeaTqN0QcyzW2DjqBYWv6Z3V3tcP8G2D+BrVwoGWKcdPkVU4/wC+K7igArz9YSfie8RGV+1DUAc9CLMwfyY/pXoFcQ0uPjTHAqYU6C8rMO5+0Kozx6f54oA7eiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW8PaFNYeOvFuryRhYtTFoI2yCW8qNlPHbk966migAooooA5Xx/olxrcXh9bVN5s9ZtL1/mxhI2JJ/+tXVUUUAFZPi+zm1HwnrdlbLunubKeGNc4yzRsAPzNa1FAGX4Ws5NP8MaRZTArLbWcMLgnkFUAP8AKtSiigArmfDOjzWHinxhqEybU1K8geE5+8iWsKZ/76DD8K6aigAooooA5q48PSSfEix8Rgx+TDpU9gwP3tzyxOpHthH/ADrpaKKAKmsWEWq6Te6dcl1gu4Ht5ChwwV1KnHvg1JYWsdjY29pBnyoI1iTJydqjA/lU9FABRRRQBS1ywGq6LqGns+xbu3kgLYztDqVzj8aXRbEaXo1hYK29bW3jgDYxkKoXP6VcooAKKKKAOc+H+hz+HfC8OnXTI0yT3MpKHjEk8kij8AwH4V0dFFABXNLotwPiRLrpC/ZTpKWSndzv85nPH0xXS0UAFFFFABR2oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKBwKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikYgDJ+lAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANWRHZ1R1ZkOGAOSpxnB9OCD+NOrG1iyniuhqulJuvY0CTQAgC6iBzsJPG4ZJQngEkHAYmtDTr2DUbOO6tH3wyZwcYIIOCpB5BBBBB5BBBoAs0UUUAFFFFABRRRQAUUUUAFFFFABRRz3ooAKKqarqFtpWny3t6zrBFjcUjaRiSQAAqgkkkgAAZ5rFuvGmlWcPnXsWqWtuGCtNPptwkaZIALMUwBkjk8UAdLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWXq+uWmlX2lWl0twZdTnNtb+VCzqXClyGI4X5VZsnsp9KANSisvQNctNdguJrFbhUgne2fzoWjO9DhgAeuCCM+1alABRRWF4a11tYvNbgktzAdPvWtoyf+W0YUfvB7b/ADF+qGgDdorC1LxPZWlw9tax3OpXUTATw2CCZ4F7s/PGBzt+8f4VNVYfHnhqfm11RLlQVEjW8TyrCzHAWUqpEbEgja+DnjFAHT0Vxmq+NbUaz4eh0a90+9tLubN40cyyMkLgRxsoB7zSQrnHQmug1TXdM0t1jvbyNJ3+5AmZJn4Jwsa5ZjgE8A9KANOiuZPjTTIZI4b+HUbO9kP7u0ltHeaRcZ3qqBtygckj7vG7BIFZniX4haVF4ZvLjw5qenXusFQlnZmZRJJKxARfLJDc5B6dOelAHc0VRbV9Pj0uLUp7y3gsZY1lWaaQRrtYZBycdjWRF410hnV7k3NlYyY8i/vITDbzkjOFdsY46bgN38O7BwAdLRWJpPivQdXm8jT9VtJbgoJBCX2yFD91wjYJU5GGxg5GCar+C/EZ8RJq7lI1Sz1CW1iZDkSxrjbJ+J3D04oA6OisLUfFFhZXb26Jc3jwqHuTZxGUWyHo0mOnrtGWxzjHNVYvHvhaW4SEa3Zr5jbYZHbZFOchT5chwsmGIU7ScEgHBIoA6evMPi545sPhVbprbATyai7RnTQ+wzyKoxKpwduPlVuMEEdwA27pPiptS8f3WnWk9pdaIbEPDPCwbFwhUyLuBwcpNCQPY1H4p1Hwz4p0+50Y2Nv4qYtseytwsqxtjq0n3YiBn5iwPYZPFAFz4X+L4fHXgbS9fhjWF7lCJoVbPlSKSrL9MjI9iK6qvB9H0iLwV4W1zSfAc2ria7uUujpsihpdKZCDPvlBwVKIFUZJbjBYNke0Xmt6XZacl/e6jaW1k6CRZppljQqRnOSR2IoA0KKwbXxfoNzPHEmpwo0oJhaYGJbgDqYmcASAdyhOMjPWp7vxLolrDLLNqtkFiZVcLMrEMxAUYGTklhge4oA16K5vxT4lWy8D6lrmgvb6lLHbl7QRv5iTSkYjXK9csVHHrW7aXUV1ZQ3UbfuZY1lVjx8pGQfyoAnorl5PHOhxOzSzzLZb/KjvhEzW88mP9XG653N2AHVvlGTxUp8ceGV81ZNcsIZo0MjwTzCGVQM5yj4YYwQcjgigDo8DIOBkUVyvgXXpLrwTp954hmht76MG1u3kcKrTIxRmzwBuK7gP9rFOm8aWCOZYba8udIRgsuqwKrWsZ5B+bduZQR8zqpVe5GDgA6iisbTvFGiajefZbPUreSck7FJ2+aASCYycCQAqQSuQCMVDYeIxdeMdT0JrYx/ZIY5I5ywImYgGRcdtokh+u/2oAf4x/wCQRAPXULEH6fa4q0dYiWfSL6FwGWSB0IPQgqRWZ42YLo1sT31LTx1x1vIa2rhS8Eir1ZSB+VAEGjnOkWJByDAnP/ARVusrwnKs/hfSJEIKtaRHg5/gHFatABRRRQAUUUUAFFFFABRRRQAUUUUAFc74o0zUb/WvC1zp8do1vpuoNd3JnnaNtht5ocIAjBj++Lclfu475HRUUAc54J0zUtLstQj1VLNJJ9QuLuP7NO0o2SyFwCWRcEbsd+lT6n4dS8uJLqDU9Vsr0kFJoLpiseBjAhfdEQR1yh6564I3KKAOdg8IafFCiC71kkAb3/tW5UyHuzBXAyepwBXL6jpsNt42g0G0RxY6hBbC4Uys5aKN7yZ9zMcsHcqrZJyHOeK9KrLm0WGXxPa62ZJBPb2ktoI8/KVd423H3Hl4H+8aALtnaW1jbrBZW8NvAv3Y4UCKPoBxUwVVztAGfQUtFAHNeM7e0svD010sEMKwXFtcyOqBfljnjkJOPQKTT/AtkkXhuwvJoFW/vY/tlw5Ub/Ml/eMCevBbA9gB2rT1/SrbXND1DSr7f9lvoHt5dhw211KnB9cGr4AUAAYA4AFABTHhikdHeNGdCSrFQSuRjj04p9FAHAfDWy03U7CPU2hiuXtoobG2kkAfyUjhj3qmfunzC4bHUqM9K751V1KuoZT2IyKzPDeh2XhzSl07TEZLVZZZgGOSGkkaRufTLnHtitSgClqmk6dq9uINVsLS+gB3CO5hWVQcYzhgR3P51xeo2djP46HhwW6fYri2gvZ7dBsjaJBMm0gdRv8AKOOhxg8cH0Gso6FaHxSuvlpvty2RsQu75PLLhyceuQOfSgC3punWWlWaWmmWdtZ2qZ2w28SxoueuFUACpZreGeIxTwxyRHqjqCDznofepaKAPP8A4mxLbR6Fa2KLAdRvDpn7oBNqTjEjDHcKrH6iu8ghit4UhgjSOJAFVEGAoHYCq9/pttfz2E11Hvexn+0wHP3ZNjpn3+WRvzq5QA2Rd8bJnG4EV598HIbTUvDNnrpiimuZYIbeK5ZMsscUSRlFJ5C+YshwO7GvQ6z9A0ey0DSYdN0uHybOEsUTJONzFj192NAFu7toLy3eC7gingcYaOVAysPcHg1Si0DR4ZoZodJ0+OWFi8TrbIGjY9SpxwT7VpUUAYkvhPQpdTF+2l2wu/NWcuq7Q0inIcqOCwOPmIzwPQVyvgixsvEumxrqMD3Nlp1ta2CW8zsYWdYVd2Medrf6xR8wP3frXotZHhfQbfw5pZsbSSaWMzzTl5Wy2ZJGfH0XIUeyigDWVVRVVFCqowABgAUjoj43qrYORkZwadRQB5/4dtbTVfG2uR3KRXEekyuEjdQyrJcYdiQejBVHPpIfU136KqKFQBVAwABgAVR0/SbWw1DVLy3VhPqUyz3BJzlliSMY9BtjX8c1foApahpOnalZi01HT7S7tBjEM8KyJxyPlIx2FcJ4q0Sw0i8srHRLSHTor+0ubJjaII9rTy2kW8Y/iC8g/wCxXpFYXiDQDq+r6Be/anhXTLprh4gMicGNlCk9sMUb/gOKAG2fgzwxZXENxZ+HNGguIWDRyx2USujDoQwXIPvW/RRQBhXfg7wzeXEk934c0aeeRizyS2MTMxPJJJXJNT6Z4a0LSrgT6XoumWUwBUSW1rHGwB6jKgGtaigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAopCAwIYAg8EHvS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorAXXWPjyTw/sTYumrf78HcSZWTHpjj9aAN+iiigAorl/ibrdz4c8EajqtiwW4gMQUlQwG6VFPB9mNdRQAUUUGgAornPhzrkviTwRpGr3BHm3cO9sDHOSOnbp0ro6ACk3DcVyNwGSP8/SlrhtIncfGXxHCzHY+j2Owf7kk+f8A0YPzoA7miiigCtc31tbXNpbzyqk125jgQ9XYKXIH/AVY/hVmuJ8Yb2+IfgJFbCJPeTMPXFuUH/oyu2oAKRSGAKkEHkEd6ivZDDZzyg4KRs35CuP+CczT/CTwk7klhp0SHPX5V2/0oA7aiiigAoorF8G69H4m8O22rQxeSk7SLs3ZwUkZDzgd19KANqiiigAormPBmuXOtah4riuCnl6bq7WMAVcYQQQvz6nc7c109ABRRWVqOtw2Ov6RpUiMZtSExjYHhfLUMc/gaANWiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuLECj4zNcA4Y6AIyMdcXBP6Z/Wu0rkVnLfFApjhNOaPg9y6N/jQB11FFFAHE/GeIz/DrUYht+aa1+90/4+YjXbVynxQXzPB91EQCsjLnPt8wI98qK6WzlE1pBKDkPGrZ+ozQBNUN65jsrhwSCsbHI+lTVneJJfs/h3VJuf3drK/HXhCaAOX+CWR8NNLRgF8uS5jAHYLcygD8hXc1yXwvtxZ+ExaBSpgvbxCCc4P2iQ/1rrcjOM80AFcFpxRfjFqLAnfLZSRkevli1P8A7W/Wu9rgtOJ/4Wxd/KSPLvBnHA/daZx/P8qAO9oqG8u7eyiEt5PFBGXWMPK4UFmYKq5PckgAdyamoA4rxcwX4geDmZwqKt32zknyVA/8erta4HxnKq+PPD+Rkxxgdem+5gH/ALLXfUAUdefy9C1F84220hz6fKa5z4RRLb/D/TrdCClvJcQLg5wEuJFA/ADFbni1inhXWWAyRZTHH/AGqp4FTy9EuE2hQNS1DAHTH2yagDoKKKKACuB+BcQg+GGlQhixjkuQxPqbiQ/1ru5pBFC8jdEUsfwrj/hLF9n8JLADkJMxHtuCvj/x6gDs6KKKAOE+GEDQ33i5224uNYuJhjrxI0fP/fuu7riPh0CNQ108BZbiWYKCTjN5dDP47a7egArgvGO7/haXw9KPgBr8Ovcg2/H4ZArva4LxgzL8SfBsgXKxefk44G9Qgz+dAHT+Lruaw8K6xd2svk3EFnNJFJtDbHCEqcHg4OODVGXQtaNuwg8XaitxtO1pLS1ZA3YlRGCR7bh9RUvj9DJ4I15B1aylH/jprfoAp6Ldvf6NYXkqqklxbxysq9AWUEge3NXKyPB27/hEdE3tub7DACc9T5a1r0AFFFFABRRRQAUUUUAFFFFABRRRQBBf2y3tjc2sjOiTxtEzRsVYBhjII6HnrXlOmXd74s0LxBHqmpy6aNM0ebQrq7fcqJfMCJ5yMjIUJCytnpI2CMkn12igDjfhpcwTWmqxWkenPb2155SXmnAiC7/doxZQWboW2HDMMqec5Al1zVNXj1iebS43m07SRGbu3jiDyXRcEuqdw0aFJAB97dtrraKAOfTxloDXMdu+opBO/RLiN4T9TvAwD0BPBOQMkVz+l3sFx48ubyCZJIJL97FJEYMj/wChQy8Hofut0J+6fevQKwPEPhPS9ctY7e4jeCNbv7Y/2fCea5RkcPxyHRmVu5BPNAEHiO5bVbqDQtJ1GW2uZczXNxaMpktolHBycgMz7AARyN/oaih8WyWtqItU0bWv7RiGyZbXT5JY2bONyOoKlWPI5yB97bzXRWFhaadb+Rp9rb2sGS3lwRhFyepwOKs0AefeI9btfEL6JpcEN5Be3F24ktbu2eJ0C20zHO4YIyFGVJByMHnNa+meKNNtPB2mXt3dR+a+nwzrbqwM0mYwQqp1Zj0AHU11VZXh7QNO8PWRtdLhMcRcuS7l2PoNzEnAGFA7AADgUAc5paa34Z3yz2Wqa4uo4uZ44J43a1uT99V810AixjaFPBU8fMKj8ReL7a58L65Bc6frGm3D2s0cK3li6iXdGQpVgGTkkDaxDZ6qK7yigDmvDtzb6c+rW15cwQkanN5YkkC7t4WXAz14krJ07SrzVtQHi+ynWHUZS0drHMCY3sTjbGwB43FRKG6qXxgjIO/J4V0ebV9Q1G6s0upr6JIpkuP3se1cdEbIGdqZx12LnoK2wAoAAAA4AFAHPm48UwyJJJYaVcQ4+eKC5dZBwfull2nBx1xnJ6YweZfUTo+vQeINdtZ9Miu7m5tvJkAlkLNHAqBRGWLFvsxKhck5H0r0emvGkhXzEVtp3LuGcH1HvQBx17Zp44ufKvLS9h0GCGQbbmBoHnmkRo8hXAYBEZ+qgFnBH3KuqPF9vDDCn9iXbIAGuZXliaTA6lFUgFvY4XrhuldNRQB5z4ottVe5vdY1ayitrexbTnja3nNwGSO68ydsbVIwmO3b2rRvtYj8W6emj2unarGl+fLvPtVpJAsVseXyxGDvX5AFJPz54wcdrRQB5zrGrQaB4K1fQb4XUNxb28tpYvJGzrcRsCsG1wCGIBVGzyCCSMEE9T4UIji1WDkCHUbjOT/fbzf/AGpW7XOX3hGx1DUby4vrnUJoLpleSyFy0duSECHcqY3gqq5Vyw46DJyAZtl4i1Eakup3ikeGbySSCArFkwBCBHOxGTslxIcngDyumSa3j4m0FSAda0zJOAPtUeSfTrWqiLGipGoVFGFVRgAegp1AHJ654t0Kfw9q/wBg1nTbqaOymkEUN0jswCN0AOT0P5U/wKnkSa9bYAMF9GpwMdbS3b+v6Vt6zpGn61Yy2erWcF3bSjDxyrkH0+hHYjpWZfeForzVru7fUNRhgukQS2ttN5CuyjG4umHzt2jhh0oAx7u81GTXbjX7NrufTdPnFgbSAGQTw4HnTIg+86yFRxk4hcAZbB1ofGugPLJHPetYlF3E6hBJZqcZyAZVUEjHIHIyM9RW7Z20Flaw21pEkNvCgjjjQYVFAwAB2FTUAcL4EvLaOR7hpoo7e7sYrqJywCsr3Fy+QenSRfzq1q+tX9zfSzeH5fPsdJCyXaRIJPtZJBaFDgncseWwOrMgzjcK29Q8O6PqN3Y3N/ptpczWSstsZYwwiDAA4B47D6dq0LW3gtIEgtYY4IU+7HGoVV78AcUAZX/CV6ADEr6zp8by42LLcKjNnsAxBznjHY8VieIozJ4wim+ULax2RLH/AKaXJXH/AI6a7KeGO4hkhnjSWKRSro6hlYHqCD1FcxdeDLG10zUI/DMVvpV5ctBIrhC0QeF98eYwwG3PBC4yDQBEl3rXijwoHi07T7e31SzDRs985dFkTIJUQ4yAegP4966+quk2SabpdnYxMWjtoUhVj1IVQAf0q1QBy3h6DxLpWlw6fPa6TdJbZjinF7JGXjB+TKeUcELgH5jyPfjZspdVeZRe2VlDFg5aG7aRgfoYl/nWhRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXgn7S99Pb+J/Atqurppdpcx6kJpJ76a0g3LFGULtEQ3DEbRzk4HQmgD3uiuK+C2oXmq/Cvw3eakL4Xj2oEpvmzM5Uld5PUhsbgTyQRmu1oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbI6RRtJIyoigszMcAAdSTXHWvj611CKX+zLC6mnOpjS7eOXEQuHNutz5gJziMxEsCRkgdOa6fWNNtdY0y50/UI2ltLhDHKiuyFlPUZUgj8DXIw/D8WN7d3ul6nMl4+qJqdu14ZbpYitoLUoweXL5UyHcCp+ZRyEFAD7r4gwR6ZDeW2m3U4Wzmv7uIOga2ihbZIDzhnDBgAODsbkcZ6jVNYsNLs47q+uFjglZUjYAsXZvuqoAJJPYDk1wV/4Vs4vsuhQeJrK11W8sLmxuYpYlaW6SZjLJJFHvBRgTIQfmUBuQcCunu49M8RPaWmmaraNJo9/HLNFC6ysjR5HlsA2VP19OlADoPG3h6ZXZdSRESGSdnljeNQsfEgLMANyZ+ZPvL3ArX0rUrbVbYz2Zm2KxRhNA8LqR2KuAw6jqO9cpL4E32sUJvYJRHcanOUuLTzI5Ptkskmxk3jKr5mDz82P4c8bPg3QZvD2nXFtPfteebcNMow4jgUqo8uMO7sFypbBY8s2MDAABvUUUUAFFFFABRRRQAUUUUAFFFFABRUF+88djcvZxLNdLGzRRs20O4HygnsCcc1zukeLRrNxaLpdoZ45dJXU5BvCshkOIoueAW2zZJIwY/c4AOporG8H6zJ4g8N2WpzWwtZLgMWhD79hDFcbsDPSq954hvra4niTwtrlwsb7Vlha12yDP3lzMDj6gH2oA6GiuPl8dW9jdxxa3peo6VHckJZtcKrNdS5A8tEjZju+YYB6gMegJqGz8V6rqVpPHDpA0/Ujqo06GG8cNsTylm82QIevlktsDdcDIoA7aiuWvfCtxq6yf27rV5MdpEKWJazjhY9HAVizMMcbmIHYVTOveKbCyFvN4VuNQvbZB513HdQpBcKuNzRjJk3kchCgGeN2MEgHa0Vx3/CX3d1qelrp+i3Q0i5vDbSX12PJ3fI5BjiPz/fUDLKowCRngmW2i1rxHaySzakum6fJNIiRWUX794lcqpMzE4LBc/KoIDYByN1AHWUVyEOl6n4YuZV8O2w1DS5wD9lub1w9vKBgsrMGJRhgkdQwJAO44ZB4n1tbiXTbnw7NJrKuxUQMRaGLaCJPPZQOrbdoBfKk7QKAOyorhtJ1rWvEVlo9vFPb6bdTWJub64gj83y5A4QxxBuOWEnLbsBQMc5Fm88FRbI760upZvEcEy3EWp3hDyORwY22gBYmXKlEAHO4DdzQB2FFclc6z4l08xXeq6La/2eDsmi02WW9uBlWO9QI1yAwVcAE/MWyAuDSn8Va9A+rpd6RaWs0enLdWNubgyuzlmUiUgAAZMYwpPRuTkYAO6rgdX8d3th8TdP8AC8eizS2tzEztehZNikNAMlgmBjzWBHIy0WWXccaqeE3vZN/ifVrrWo87hZvGkNqpx/zzQZccniRnHTuM1laiPEPg/R5G0+PTb7R9PzKJ7yeX7TFahtzxBdpDlUGFcuOFG4EjJAO+orgPDPjnWNQ0i2vdS8HavFE6l5J7YxSRhCSVZU8zzHBTYflUnLYAyK2rvxM10bKLwvbQatcXUP2oF7nyIY4c4DO4ViMnIACkkq3TBoA6WiuZbVvE0P8ArfDEEpH/AD66krDv03on+TVNPGV1Z3iWuv6Fc2NzdHGnwQSfaXuSC25SVARGAUNyxG1s54IAB2VFcRp/iXWtZstNhgs4NK1O6ubuOZLn9+LaOCRl6IwDOf3f8WBk9cYNy78JT3sMst5r2pSaoPmtrhJDFHbMPukQoQrD137iQSM4OKAOrorkJte8TWUQkvvDURgt2T7XNBeeYWQkBnhjVCz7R8xVtpwCBuPBjtfGN7NrVgk+hzWWi3iTtDeXMgWRyi71PldVVlDH5sMOMgc0AdnRXGaXp+seJ9GsbvXdWe1t7uJJ3sdMBhG1gCIzNkuRzyVKZ9hxUtrZ6/4d8+y0ezt9T01n32n2q/eN7YH70bko5ZAclSMkA7cYUEgHXUVwepeMNet9NvI7PwrdXGr2kbtOzt5NmhBO1llcAyKyjdiMMRwG2k1oNean4g1O4tdL1H+zLKCCGRp4oVkmd5AWwpcFFAXb1Vslu2OQDrKyPFeh/wDCQ6NNp/8AaWpaZ5g/4+NPn8mVeOzYNYsnhSTSZ7bVdBmuLnVoiRcm9uWJv42ADK7chSCAy4UKCMAKGNI/irWbE7tY8MXEKTjbaRWk32mV5cgbJNqhI85yGLlcKSSMYoA8m8Hfs+ap4U+KmneI7XxObuxhaZpJZE23YLxOg+8HRuW5Jxxniq1r+zhqd18QNY8Qal4snsYri/nuYW07K3TK8jMC0mFVG552gj6V6xB4r1u7gv7eTS4tL1QalDYwRyuLjy45I0fzH2EAkDzDtDY4Az1rRuPB39pCR9e1jUb+fYVhMcn2aO3JH3kSPGWB5DOWI7Ec5AOg0ix/s3ToLT7VdXflLt866k8yV/dm7mrdcc994zsdPKHSNNv5bVf3lwLxka6VepSIRnDsP4S2ATjJHNR/8Jje3Gp6S1po08GhXV39me9vswyPlG2eXCfnGZABlwvAJAOQaAO1orj9Pi1jxPZNeS6vLpthNLIIoLKJVkMSuVUtK4JBYLklQuN2AcjcVh0m/wDC1zM3hy0+36XcAM9jJdFZIZQAC8bPkEMMbgSPmG7JLNQB19FZPhy81S8tZ/7c0+Kwu45doSGYyoylVYEMVXONxU8dVOOMVrUAFFFFABRRRQAUUUUAFc74f8JWXh+PWBpc93HJqU8k7Ssyu0BbJCx5UgIpZiqkEAseo4roqKAMfwpoSeHNHj02K+u72GNmZHuvL3qCclfkRRjOTyM89emNiiigBGVWxuAODkZHQ1xBz/wnHlZb/kLrPjsB/Zzp/MCu4rz4kf8AC5/JLD/jxFwFx3AKZ/I/rQB6DRRRQBzvjZmjtdKmQZKapaA84wGlCf8As1WfBp3+FNJl/wCetskvT+8N39ao/EVN2gWzcfu9V06Q5OOBewk/pmrfgRBF4H8PRjIC6dbqMnPSJaANyiiigDz/AOG0gk1bVIwOLdHjUYwRi/vVP/osV6BXCfDqDydc8RDDAiaTO7r819eyenT5+K7ugArhPGcgg8Y6XncBcWyxk5wCPt1opH/kWu7rzz4kAJ4u8JyEAl38geuTe2L8fhGfyoA9DqK7t4ry1mtrmMSQTI0ciN0ZSMEH8DUtFAEVpbQ2dpDbW0YjghRY40HRVAwAPwFVdO0fTdNubu406wtbWe8fzLiSGJUaZsk5YgcnLMee5PrV+igAooooA4jw2wXxjdwYG6Ka/wCn+01q/wCH3/8AOa7evPPD04b4t+ILYdYTLIc9cPBp+Me2UavQ6ACuD+K8j29tpVzHuHlteZI6Y+wXJ5/FRXeVwfxjZU8NwMVZjvuEXacEFrK5TI9/moA7WxgFrY29uOkUaoOc9Bip6KKAK+oRedYXMRwd8TLz7g1yHwmmF3oElyQC8iWfzYwWH2G2Yf8AoRrtzyK4P4NZ/wCESXdtyotkO0Y5Wzt1PHb7tAHeUUUUAcPeWyx/ECF2AxPeQSYHOSLS6GSO33R+VdxXn+oS7vjFZ2+B8tpbz5x1wt+v/swr0CgArnfHPy6dpzjHyapZdfe4Rf8A2auirmPiMyx+G4ZGIVY9T05ySM4AvYCaALfgVPL8F6ECck2ULE4xklASfzNblZHhBlfwnorIu1WsoCFznA8teK16ACiiigAooooAKKKKACiiigAooooAKKKKACvPJUZf2gbdgAFfwzJnjqVuk7/8C/WvQ6yJdDik8XWuvB8Tw2M1iUx95XkjfOfYx/8Aj35gGvRRRQByHxeYR/DTxFMd223tTcHb1whDnH/fNbnhfA8M6Rjp9kh/9AFO8S6TFr3h3VNIuHZIb+1ltXdQCVDoVJGe4zmrdjbpZ2VvbR52QxrGufQDA/lQBNRRRQBwHw6ct4y+ICZYrDqUaAt2zCrkD2y/6139Y2iaBDpOr69fwyMz6tcpdSIQAIysMcWB658vP41s0AFcH8S8Lr3gZm37ZNYWHK4xnY0gz/36rvKoappNpqcunyXiF2sbkXcHONsgVlB9+HagC/RRRQAUUUUAFFFFAHmfh23kh+Pvi9t+YpdKs5gmejEshP5RCvTKyINCt4vFl5r6u5urmyhsmTjaFjeRwfqTIfyFa9ABXA/G3cngjz41YtHe2y/LjjzJBCScg8Yl/wD1V31VNU0601Wya01CFZ7ZmRyjEgEowdTx6MoP4UAW6KKKACvPfgiW/wCEZ1NJAwaDVbi2O7rmIrEf1Q16FWfo2kWmjw3MVirKlxczXcm45zJK5dz9Mk8UAaFFFFAHnGpK6/H3SNoJSXQ5XbnhfLlIz/5Hr0esufRLabxPZa4xcXdraTWagH5WSV4mJPuDEMf7xrUoAK4z4ykL8L/EUzLuFvbG4xxz5bB+/wDu12dZviXSYtf8O6ppFyxSG/tZbV2UZKh1Kkj3GaAI/CSeX4U0VByFsoR/5DWtaorSBbW0gt0+5Eixj6AYqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiig0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVDe3UNlay3N1IscMY3Mx7D+p9qAJqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKqXuo29ld6fbTsRLfTNBAAM5YRvIfp8sbfpVuuG8Xxyz/ETwXImzyLCSeaUFjuLSxNEmBjGPmc9e3vwAdzRRRQAVS0bUoNX0y3v7MsbeddybuuM4/pRreoJpOjX+oyqXjs7eS4ZQcZCKWI/Suc+EtrLY+A7GzuSpmtZrm3coDjKXEinGf8AdoA7CiiigCj/AGra/wBu/wBkbm+2/Zvte3HHl7tuc/Wr1eewTrP8dJXVSFi0WWzLH+J0kt5W/DbcR/r+PoVABVXVdQtdKsJb2/lENtEAXcgnGSAOnuRVquB+N80i+ALu3gKrJcNkEjOPKVpz+YhI/GgDvqKKKACuf1L/AIm3iO104c2lhtvbr0aTJ8hPwIMh7gpH2arOu+JNH0L5NT1G1huWiaWK1aVRNMF6+WhOXPbAHUgUvhmxms9OMl8F/tG7kN1d7TkCRgPlB7hFCoD6IKANaiiigClcalBBqtnp8hb7RdxySR4HGI9u7P8A32P1q7Xn2r3ksnxp0O28wLBaWDjZt5d7gSnr2wLTp/tV6DQAVX1C7h0+wub26bZb28TTSNjOFUEk/kKsVz/j5Hn8KXlmhK/bmisGYdVSeVImI9wrk0AbNjdRX1lb3ds26CeNZY2xjKsMg/kanrA+H7M3gPw2XzvOm2xORg58pa36ACqNlqtre6jqNjAxNxYOiTgjoXQOuPwIq9Xn/wAPpHuPHPje7cYW5niKDGMCJprb9Tblv+BUAegUUUUAUtS1O206WxjumZWvbgWsOBnLlWYA+nCGrtcD8SWlm8QeELeMqIra/TUJDnk4lit1X6H7UT/wCu+oAKKKq6teppul3l9KCY7WF52A7hVJP8qAG6PqdprOmwX+nTCa0mBKOARnBIPX3Bq5XFfBu2ms/h5YWl0FFxbT3cEgUkjclzKpxkDuK7WgAooooAKKKKACiiigAooooAKjkniidFllRGc4QMwBY+3rUlcb46hjl8TeBHewnuTBqzyNJHZvMsCG0nQMzKpCDzHh5JHOD/CSADroZ4pwTDKkgBwSjA4NSE461xvwvhjg0zWFjsJ7Lfq15IFms3ty6NKxRgGVcgqRgj6dq0ru58VLdTC10nQ5bYMRE0upyxuy54LAW7AHHYE49TQB0FcB4pLf8JrE+5gIDpgG3/ppcTqc/kKtatpPifxDayfbbiLRWtiJrWHTr15POmXlTNIY0Pl5AGwDnkkngVQv7LWr9NW1eTRZ7W8WbT5IrTzonknW2l8xwrBivIZwuSDnsKAPRKK51/FCuQtho2uXkh/hFk1uB/wKbYv5Gq/l+LtQjKTtpelwT/eMLPLcQKeoBI2F8cbugPOGxyAWviFlvA+uRggGa0khBJwAXG3/ANmpPApJ0e7BxldU1Acf9fcx/rXP6loOsafC2kaTate6Rd3trN50l4WmtQskRm3+YcupVHbIJbcxG3nNamm3cmgXmrWl1p1/JHLevc20ttbtMsiSAMclR8pDlxhscAHnNAHW0VzS3nii7H2i103TrS3/AILe+nbzpB6sUBWM+w3+5B4qlLY+J0mttZubhp7uGX59GsZlFs0JBUgO6qXcZD7m2jK7QFySQDK00tF8WnZlP+kNfgE8cCHThx/3xivR689httQhfSvEF1pVzFJFqV29xahRJPHby7kVtqFt5+WIkKScE4zjnel17UrsbNF0G8d2IHn3+LWFOmSQcyHg9AnOMZHWgDpK4T4vRJc6JBbsquxS9fawyCPsNyp/9DA/GtWfTNe1Ura6vfW1vp45lOmmSKa46fLuJzGvXO0lj2K85xbbRddv72w07W7dRZWGn3Nq1+twJBdO6xxo+04YMU8wsCMAnAY5zQB2ehy+founzZz5lvG+R7qDVuVxHG7scKoJJPpXHaBrV7p2g2GnT+HdYk1G0t47d44o08tmVQpKyswQrxkEkHHbPFTXyeMb3TLgRpolrLcRNGIGeVmhLDG4ygYYjPQIBx170AeC/ELwzq3xx8Y+Cp7K3ew01tDhvr64+8tt5sj5RTxuf5DgcdM+te+eEdTjjuv7At4blrKxhMFrfXE5le6MJWOUnIzlWYLknk7sAAc0tL8Ka3odkNO0bW4PsBQxrLc2oae2BYsRGVwG+8cbwcEAndyK1rrw69tp+kpoM629xpfEJnzIsyFSrJIc5O7hi3XcA3PIIB0VFc0LjxgoU/2ZoEmeq/2jMmOPXyDn8hWVqmi+JdcQXmoPa2N1YTJcafYWd67QyyIQ2Z5DGpIbDJt24UMT8xxtAK14pk+J1tcLtbbqENq3PKhbC7k/nIK9DrzqG01gyT65d6RcW0q66l6bNXSWTyBaLbMw2Ehv43wOSB0zxXT3XiRUBWx0jWb6ftGlm0IP/A5tifrQBvVz3jQ7rbSoQeZdUtQPfbIHP6IaglsvEmrW6W+o3Fnp1rKP9I+wPIZwpz+7WQ42nplwM9cAEginaaNqtvqelae9tHLo9heyXcN39oLN5ZjmCxujc7laRQCC2QoJweKANbwE2fBWiLkN5dpHFkd9qhf6VvVxPh671Dw/pLaU+g6peXNvcTiIwCIRyRtK7RsHZwo+QrkHkHPFaaL4tli89p9DtXYE/Yzbyy7fQGYSLntkiP8APrQB0def/DUqdVvpg7H7TZRTDceTm7vWJ/8AHxV8aNrek36ata3H9sXsyul9BLcNBGwO0oYEO5U2YICnGQ5JYnrT0fS9T8Krokv2GbUgmkpY3i2jJuWZGDBgHZQVJaTocjjjGSADvaK5ttQ8QahKItP0kaXH/FdamySf98RRSEt/wJkx79Kr33hfUNXSVtb1hZpkiK2i2kD28MMhziVk8xjIwOMZbAxwAeaAMfx65PiSIjefs66cxCdcNqURP4Yi5r0SuDvNC17Uf7fu76GwhvZrS1htEt7hnR3t5ZZQxZlUrlpFGMHGOprVbX9anAjsfCWoJMeN99c28UKH/aZHkf8A75Q0AdPXNfEwM/w/8QxL1mspYfwdSp/nRPZeKriERNq+l26yYEj21k4kiXPOxmkZSccAlcDrjtWJqHh7WbK0uNG0uJr7R725gfz7i+d5rZN0fnBvMyXBCuwIbO5yMAc0AdD4LXytOv4sklNTvTg9t1w7/wDs1b9clZ3dzoWp6zBc6XqE9vcXZubaa1i81XVkTcDg5Uhw3XgjBB6gWVuvEupSMbS0tNGtl+6+oL9plk/7ZxyKEHuXJ9VFAHSUVn6PZ3dqs76jfm8uZn3ErH5cUY6BUTJwMdckkkk5xgDQoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACms6qVDMAXOFBPU4JwPwB/KnVyHj6fyNS8Gdf3muJHx721x/hQB19FFFABTYpElUtE6uoJXKnIyDgj6gginVyPwtuTd+FZZC+9v7U1IE5z0vp8fhjFAHXUUUUAMaaJZ0gaRBM6s6xlhuZVIBIHcAsuT7j1p9cRq87r8ZfDUKthG0bUNw9cy2v/wATXb0AFFFcn8WrySw+GHiu6glkimj0y4MckbbWVvLIBB7HOKAOsoqKznW5tIJ487JUV1z1wRkVLQAUUUUAFFFFAEUlxDFNDDJKiyzZEaFsF8DJwO+BzUtcf4rmaPx74HQYxLNdqc/9e7H+ldhQAUUVU1idrXSb64jYK8UDyKx6AhSc0AW6KwPh9qFxq3gLw3qN7IZbq7022nmcgDc7RKzHA45JNb9ABRRXF+H7tpfip4wtmkyIbLTiqE9M+eSR+lAHaUUUUABOOtFcV8VrprXS9BKnHma/psZ+huUzXa0AFFFFAENpdQXkTS2s0c0ayPEWRsgOjFGX6hlIPuDU1cT8IJ2n8KXZfHy6xqaj6fbZj/Wu2oAKKKKACiiigAooooAKKKKACiiigAooooAK4L4pki+8FMobMWv28hYHoCGiOfr5uPxrva88+KsjDUfDgXJMV1Hclc8EJdW2T+TfrQB6HRRRQAV578CmZvAXzrtY6jfPjOeHuZHH6MK9CrgfgyBH4ZuIE2kQywjIGM7rS3fp/wADoA76iiigDz/WePjR4fkGQRYSwk54IfzGx+cOfwr0CvPfEAb/AIWvoTrjarwK/PZrfUsf+PAdK9CoAK5T4qxrP8PtbgbkTQiIDGclmCgY78murrD8ZBW0aJXzta+slOPe6iFAE/hOUzeFtGlJBL2ULZHTlBWrXOfDfd/wr3wyHXa66ZbKRnPIiUdfwro6AMnwvrtv4i0x760UrEt1cWuCQcmGZ4ieOx2ZHsRWtXm/wDJ/4Qq5RldSupXL4Y9pG80H8RID+Nej5G4DIyeQKAFooooA4PxtKkfxH+H24MT594Rg+sG3p35YV3leffEKKFvGng24kUtJbSuykH7u+a3j5Hf79eg0AFY/jN/L8H66+M7bCc/+Q2rYrE8cjPgrxAPXT7jtn/lm1AFP4Yx+R4A0K3yCLa1W2Uj+7H8g/RRXT1zvgHK+HTGRjyr29i6dkupV/pXRUAFeeeGAV+NHjVmBPm2lkqnPZEJI/wDIn869DrhdPAj+LN4VKkT29wH45BRLDH6SGgDuqKKKAOD+MCCTRtG3R+YkerQTMN2MBFd8/gVFd5XA/GhBJ4TMYx5hW7ZMjOGWxuWBx9QK76gAooooA86+BsEtr4Z1SGdi0n9rXMxJOciUrKP0kFei1w3wrcGz1AdDILO4I7/NZQDr9UNdzQAUUUUAFFFFABRRRQAUUUUAQX87Wtjc3EcLzvFG0ixR/ekIBO0Z7npXMar460+z0ibUbaGa7gj0SXXcxkAeSqhkUn+8+Wx2+Rs9s9dXIeF/Br+HYNaFpqIluLxytq81vlbSAFmig2hhvVGkk7gkNjjrQBs+GtWbWbA3e20EZYqj2t2tyjAdTuUAdeMVrVh+GdDl0mTVbi8uYrm81K5FzM0MHkxgiNIwFQsx6ICSWJJJ7YAiufDl1NczTp4l1yFndnRY2g2xAn7qqYiCB23bj70AdDXnnxRgZ7uO5ChlttIvZDxnGJ7N8/kjVvt4YuLhSmo+JdduoipGxZYrbBPfdBGjfrioIfCEkttqMGsa5qOppeWLaeGlEcbRxtu3MCij5zkZbH8I460AdXRXP/YvE6wxomt6SzKu0yS6U5Zj6nE4GfoMZ9OlMt/C5MW++1jVpr18maaK8lhRieyxBtqAdBgZ45JOSQDZ1W5Sy0u8upGCJBC8rMTjACk5/SuR+F8JtItXtj/DJaMM9f8Ajxtk/wDZKs6l8P8ASLy3vI4LjVLJr2D7NdSW97IWnjwRh95YE4Zhuxu561e1Lw9dy6hJd6Trd3pZljSOWOKGKVGK5CsA6kg4OOuMAceoB0NFc0fBml3AWTVvtGq3qnKXl3JmWI/3oiu0Qn3jCnij/hEleNhca74gmlyDFL9uMZix0AWMKr/8DVs980AYevqH8Zi5Az9nvtPiJPOCROPw/wBcPzr0GuYj8JBdPv4pdWvri+urmO7+3TJF5iSRhBHhVRUwPLHG3nJ9alu9G1q8dVl8SzW9vjDrZ2kcbt/wNt2PTjB9CDzQB0VYvitlNlZxErulv7UKD3KzI5/RSfwqv/wiNmFESX2tLan78B1KZg/1ZmLgewYA981Ha+DbC01G0uLa61CO2tZ2uI7Ez74BIVZc4YEj7zHAIGTnFAE/gMBPCOmxKciFDCMf7DFf6Vv1yn/CLajBLOmmeKNRsbGSV5lgjt7dzEXYswRnjPy7icAg4zgcYxPH4OsFbz3utUk1AgBr43sizMB2JUhdvfbjbkk4zQBg/BlUg0PU0EjMFuLdzuGNu6wtXI/8eqvdO9xqtr45V5Gs4LtLW3+chP7PcbHlx0wZGEu7ukSHpVPQfCGj3vxC8VWWp6dBeWFlFY/ZYp8uqhoAjBlPDAi3i+9nlR6CvUJrWCa0e0lhje2dDE0RUbShGCpHpjjFAE1Fc6ngvQ4gBBbXEBUYDQXk0TD/AIErg/X171HdeB9EvYHg1BL+9gcYMV3qNxMmPo0h/PrQBgfEE+d4jtAoDfY/7Pkbj7gfUoOfUcRN/wB8n3r0WuWXwXaC11OM6hqck17DDB9pmlWSWFYmZothK87Wdmy24knnNWDpfiAxqn/CRoNo4cWCbnP+182D/wABC9/wAOhrB8cMP+EV1BOvmhYMepdwmP8Ax6mR+ErE2/l3d3q927LiV5NTuAJT3JRXCjPoAB2AxxVeHwF4ftZFOn2klhALiO6a1tJnit3kjKlWMQOzOUUkgZO0ZzQBc8HYWwvowQQmpXnQYxund/8A2atrzY/O8nzE83bv2ZG7GcZx6VzkvhWT7fdTWfiDWLG3uZjPJaW/keXvIAYhmiLgHGcBupJp3/CE6CSZWs2a+Lb/ALeZX+17sYyJ87xwSMA4wcYxxQB0lcBoyu3jr7a4/wBddX8AYA4wFtlA/wDIH6Vsy+C9NleOeS51Nr+Nt6XhvZPNQ4IwOdoGDjaBg9wTUp8K2y6Xa2lre39rNbTyXMd5HIrTCWQuXY71ZW3GRuCpHPAGBgA6Giuafwp9rDJrOt6tqtq33ra4aFInH91lijTcp7hsg9DxxUjeDNCkiWCezkuLRRhbW4uZZbcD0ETMU47ccdqAMv4mILizS3bkCzvpz9BbMmf/ACL+tdhaSie0hmHIkRXH4jNYeneD9H06eN7eK4ZIrRrGKGa6kmjjhbbuVVdiADsQcdlAqK28KSW8UdvH4i1wWUShIrbzIQEUcABxH5hwO5Yn3oA6amTSLFC8jnCIpZj6AVz8fgzRoHeWziubS6fmS6gupUmmPrI+7Mh9N+cdsVFceCNKcXBt5dRtJLmIw3EkV5IWnU5++XLbiMnDHkZxnFAFH4dwm2mlhKsudL06Tn/rm6f+067asDUvDnn3kd1pmq3+kTrAts5tBEwkjUkoCsqOMqWbBAB+Y5zUD+D7a82/27qGo60EbfGt3IiJG3ZgsSou4diQSOxFAHTUVR0zS7bTFdbVrkq+Mia5lmxj03scDntir1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEEVnbxXc91HCi3E4VZZAOXC525+mT+dT0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three simultaneous electrocardiographic surface leads V1, II, and V5 show a junctional premature beat (asterisk). In panel A, there is a sinus P wave seen in lead II just prior to the junctional premature beat, which alters its initial deflection (arrow). The junctional premature beat has a QRS morphology that is identical to that of the sinus beat. In panel B, a sinus P wave is seen immediately after the junctional premature beat in lead II (arrow). The junctional premature beat has a QRS morphology which is slightly different from the sinus QRS complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31936=[""].join("\n");
var outline_f31_12_31936=null;
var title_f31_12_31937="Ocular cicatricial pemphigoid stage 3";
var content_f31_12_31937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Stage 3 ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the symblepharon bridging between the eyeball and the eyelid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31937=[""].join("\n");
var outline_f31_12_31937=null;
var title_f31_12_31938="Dorsal penile block";
var content_f31_12_31938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dorsal penile nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dorsal penile nerves are located beneath Buck's fascia at the one- and 11-o'clock  positions. The sites for injection in dorsal penile nerve block are at the two- and 10-o'clock positions (black dots in A) with the needle directed medially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31938=[""].join("\n");
var outline_f31_12_31938=null;
var title_f31_12_31939="Bladder cancer diagnosis and staging";
var content_f31_12_31939=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/12/31939/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31939/contributors\" id=\"au2830\">",
"       Yair Lotan, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31939/contributors\" id=\"au1991\">",
"       Toni K Choueiri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/12/31939/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31939/contributors\" id=\"se2767\">",
"       Seth P Lerner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/12/31939/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31939/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/12/31939?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLADDER CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cancer of the urinary bladder is one of the most common cancers. The most common type of bladder cancer in the United States and western Europe is urothelial carcinoma, also known as transitional cell carcinoma (TCC). Other types of bladder cancer are also found occasionally, including squamous carcinoma (which resembles skin cancer under the microscope) and adenocarcinoma (which has a glandular pattern, similar to bowel cancer, under the microscope).",
"    </p>",
"    <p>",
"     In other areas of the world, such as the Northern African and Mediterranean regions, squamous carcinoma is seen more often, although urothelial cancers (or TCC) remain the most common tumors there as well.",
"    </p>",
"    <p>",
"     This topic will discuss the symptoms, diagnosis, and staging of transitional cell carcinoma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BLADDER CANCER RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Bladder cancer is more common in men and in those who are older (the median age at diagnosis is 69 years). Other factors that may increase the risk of bladder cancer include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Exposure to chemicals",
"       </strong>",
"       &mdash; Being exposed to certain chemicals or industrial compounds in the workplace or the environment can significantly increase the risk of bladder cancer. Of particular risk are a type of dyes that include \"azo\" compounds. In most cases, it takes many years after the chemical exposure for the person to develop bladder cancer.",
"      </li>",
"      <li>",
"       <strong>",
"        Cigarette smoke",
"       </strong>",
"       &mdash; People who smoke cigarettes have a two to four-fold increased risk of bladder cancer compared to never smokers, with long-term heavy smokers having a six to ten-fold increase in risk. Exposure to second-hand smoke also increases the risk [",
"       <a class=\"abstract\" href=\"mobipreview.htm?31/12/31939/abstract/1,2\">",
"        1,2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       <strong>",
"        Family history",
"       </strong>",
"       &mdash; A family history of bladder cancer probably increases a person's risk of developing the cancer, especially in those who smoke cigarettes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BLADDER CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The initial signs and symptoms of bladder cancer are often mistaken for those of a urinary tract infection or kidney stone. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Symptoms often come and go and are not severe. The most common symptoms include the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Hematuria (blood in the urine)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common sign of bladder cancer is blood in the urine (hematuria). Hematuria caused by cancer is usually visible (turning the urine pink or red), intermittent and does not cause pain. However, people with microscopic hematuria (when blood is visible with a microscope but does not change the color of the urine) also may rarely have bladder cancer. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, hematuria occurs commonly in people who do not have bladder cancer. In one study, only about 10 percent of people with visible hematuria and 2 to 5 percent of those with microscopic hematuria had bladder cancer [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/12/31939/abstract/3,4\">",
"      3,4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Anyone who is over 40 years old who has visible blood in the urine should have a complete evaluation of the kidneys, ureters, bladder, and urethra. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Bladder cancer diagnosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain may also be a sign of bladder cancer. Pain may develop in the flank (the sides of the mid-back), above the pubic bone, or in the perineum (the space between the vagina or penis and rectum). Pain in the flank region can develop when there is complete or partial blockage of the ureter (the tube connecting kidney to bladder) (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ) on that side, with the pain being due to back pressure of urine.",
"    </p>",
"    <p>",
"     Pain can also occur during voiding (urinating); this is called dysuria.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Voiding symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although most patients are asymptomatic, voiding symptoms, such as needing to urinate frequently or urgently during the day or night and leaking urine on the way to the bathroom, are seen in some people with bladder cancer. However, most people with these symptoms do not have bladder cancer, but another condition, such as overactive bladder, a urinary tract infection, or an enlarged prostate. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=see_link\">",
"      \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Others symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other symptoms of bladder cancer, such as fatigue, weight loss, and lack of appetite are not usually present until the late stages of bladder cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      BLADDER CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Anyone who has signs or symptoms of bladder cancer should have a complete evaluation of the kidneys, ureters, bladder, and urethra, especially if the person is greater than 40 years old. This evaluation includes one or more urine tests, cystourethroscopy, and an imaging test of the kidneys and ureters.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Urine tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several urine tests may be recommended in people with bladder symptoms.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Urinalysis is a test that uses a chemical dipstick that changes color in response to the presence of certain features in the urine, such as white blood cells, red blood cells, and glucose (sugar). The urine is also examined with a microscope.",
"      </li>",
"      <li>",
"       Urine cytology is a test in which an experienced pathologist examines a sample of urine with a microscope to see if there are abnormal appearing cells shed from the lining of the bladder. A pathologist can often identify whether abnormal cells are actually cancerous.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imaging tests can help to detect any masses or abnormalities in the kidneys, ureters, bladder, or urethra. The optimal imaging test (IVP, CT scan, or kidney ultrasound) depends upon the individual situation.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        IVP",
"       </strong>",
"       &mdash; In an IVP (intravenous pyelogram), a radiopaque dye (one that is seen on x-ray) is injected into a vein. The dye collects in and is excreted by the kidneys. As the dye passes through the kidney and into the bladder, the urinary tract and any masses are visible on x-ray.",
"       <br/>",
"       <br/>",
"       There is a small risk of having an allergic reaction to the dye. People who are allergic to contrast dye, iodine, or shellfish should let the radiology specialist know of their allergy before the test. You may be pre-treated before an IVP to avoid having an allergic reaction or may have an alternate test.",
"      </li>",
"      <li>",
"       <strong>",
"        CT scan",
"       </strong>",
"       &mdash; Computed tomography, or CT scan, is an imaging test that examines the structure of the kidneys, ureters, and bladder. The CT can show the extent of a cancer, determine if there is a blockage in the urinary tract, and determine if the cancer has spread outside the bladder. CT scans usually require the use of contrast dye.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Cystoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cystoscopy, also called cystourethroscopy, is a procedure that is done to examine the lining of the urethra and bladder. It can be done by a urologist in an office setting or in an operating room. When performed in the office, a numbing gel is applied to the urethra to decrease discomfort. A small tube with a camera (cystoscope) is then inserted into the bladder through the urethra.",
"    </p>",
"    <p>",
"     Using the cystoscope, the physician examines the lining of the bladder and urethra. If abnormal tissue is seen, a biopsy can be taken. Biopsies may be done in the office or in the operating room. The biopsy specimen(s) is examined with a microscope to determine if abnormal or cancerous cells are present.",
"    </p>",
"    <p>",
"     Patients who are referred for a second opinion to a specialized bladder cancer center may have a repeat cystoscopy to characterize the tumor in more detail and to help in planning of treatment [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/12/31939/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      BLADDER CANCER STAGING AND GRADING",
"     </span>",
"    </p>",
"    <p>",
"     The treatment and prognosis of bladder cancer depend upon its stage, grade, and risk that the cancer will recur.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bladder cancer staging is based upon how far the cancer has penetrated into the tissues of the bladder, whether the cancer involves lymph nodes near the bladder, and whether the cancer has spread beyond the bladder to other organs.",
"    </p>",
"    <p>",
"     After the diagnosis of bladder cancer is confirmed, one or more tests may be performed to stage the disease. This may include a chest x-ray and CT scan or magnetic resonance image (MRI) of the pelvis.",
"    </p>",
"    <p>",
"     The most commonly used system for staging is the TNM system (tumor, node, metastasis) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/12/31939/abstract/6\">",
"      6",
"     </a>",
"     ]. Combinations of the T, N, and M classifications are grouped together (stage groupings) to describe four stages of disease. The tumor (T) stages are defined as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       T0: No tumor is found in the bladder.",
"      </li>",
"      <li>",
"       Ta: The tumor is only found on the inner lining of the bladder.",
"      </li>",
"      <li>",
"       T1: the tumor has invaded the lamina propria (tissue under the lining of the bladder)",
"      </li>",
"      <li>",
"       T2: The tumor has grown into the muscle layer of the bladder, either superficially (stage T2a) or deeply (stage T2b). Stage 2 and higher tumors are considered to be invasive cancers.",
"      </li>",
"      <li>",
"       T3: The tumor has grown through the bladder muscle into the fat layer surrounding the bladder.",
"      </li>",
"      <li>",
"       T4: The tumor has spread to surrounding organs, such as the prostate, bowel, vagina, or uterus.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Grading",
"     </span>",
"     &nbsp;&mdash;&nbsp;A cancer's grade refers to how the cancer cells appear under the microscope. Grade is one factor used to predict how likely the cancer is to recur after treatment and ultimately, the person's chance of surviving his or her cancer. Bladder tumors are classified as either low or high grade.",
"    </p>",
"    <p>",
"     In noninvasive tumors, the grade may be low or high, while almost all invasive cancers (tumor stage T1 and greater) are high grade.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Low risk versus high risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several factors are used to describe a bladder cancer as low risk or high risk, based upon the likelihood of cancer recurrence. These factors include the size, number, and appearance of the tumor(s), if it recurs, and how deeply it invades into the bladder.",
"    </p>",
"    <p>",
"     A person whose cancer is low risk may be able to have less aggressive treatment and follow up, whereas a person with high risk bladder cancer may require more aggressive treatment and more frequent follow up.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      BLADDER CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of bladder cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=see_link\">",
"      \"Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"      \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H170290592\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14514321\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/21/39250?source=see_link\">",
"      Patient information: Bladder cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14514338\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/53/10066?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/16/9474?source=see_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/39/13939?source=see_link\">",
"      Patient information: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35367?source=see_link\">",
"      Chemoprevention of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29431?source=see_link\">",
"      Experimental systemic therapy of metastatic bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/39/5749?source=see_link\">",
"      Laparoscopic/robotic-assisted radical cystectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41992?source=see_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40409?source=see_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=see_link\">",
"      Screening for bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/34/32298?source=see_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/bladder\">",
"      www.cancer.gov/cancertopics/types/bladder",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/bladdercancer.html\">",
"      www.nlm.nih.gov/medlineplus/bladdercancer.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-risk-factors\">",
"      www.cancer.org/Cancer/BladderCancer/DetailedGuide/bladder-cancer-risk-factors",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Bladder Cancer Advocacy Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.bcan.org/\">",
"      file://www.bcan.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/12/31939/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/12/31939?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/1\">",
"      Alberg AJ, Kouzis A, Genkinger JM, et al. A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol 2007; 165:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/2\">",
"      Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990; 322:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/3\">",
"      Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/4\">",
"      Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology 2001; 57:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/5\">",
"      Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31939/abstract/6\">",
"      Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22:1435.",
"     </a>",
"    </li>",
"    <li>",
"     Raghavan D, Tuthill K. Bladder Cancer &mdash; A Cleveland Clinic Guide for Patients, Cleveland Clinic Press/Kaplan Press, Cleveland 2008.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_12_31939=[""].join("\n");
var outline_f31_12_31939=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLADDER CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BLADDER CANCER RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BLADDER CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           BLADDER CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           BLADDER CANCER STAGING AND GRADING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           BLADDER CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_12_31940="12 lead ECG atrial fibrillation";
var content_f31_12_31940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    12 lead ECG of atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows atrial fibrillation. The QRS complex is narrow, P waves are absent, and the baseline between successive QRS complexes shows irregular coarse \"fibrillatory waves.\" The QRS complexes occur at irregularly irregular intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31940=[""].join("\n");
var outline_f31_12_31940=null;
var title_f31_12_31941="Black widow spider (Latrodectus mactans) antivenom: Drug information";
var content_f31_12_31941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Black widow spider (Latrodectus mactans) antivenom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/36/21059?source=see_link\">",
"    see \"Black widow spider (Latrodectus mactans) antivenom: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/23/43381?source=see_link\">",
"    see \"Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antivenin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites (case report of antivenin administration up to 90 hours after bite; O&rsquo;Malley, 1999). However, delayed administration may decrease effectiveness (Edberg, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sensitivity testing:",
"     </b>",
"     Intradermal skin test or conjunctival test may be performed prior to antivenin administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum in NS; evaluate after 10 minutes against a control test (intradermal injection of NS).",
"     <b>",
"      Note:",
"     </b>",
"     A positive reaction is an urticarial wheal surrounded by a zone of erythema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conjunctival test: Ophthalmic: Instill 1 drop of a 1:10 dilution of normal horse serum into the conjunctival sac",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Desensitization:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15- to 30- minute intervals. During this procedure, proceed with the next dose only if a reaction has",
"     <b>",
"      NOT",
"     </b>",
"     occurred following the previous dose. Repeat procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1:1000) SubQ or I.V. proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"     </b>",
"     <b>",
"      (black widow spider) envenomation; other",
"     </b>",
"     <b>",
"      <i>",
"       Latrodectus",
"      </i>",
"     </b>",
"     <b>",
"      spp envenomation (unlabeled use; Clark, 2001):",
"     </b>",
"     If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H",
"     <sub>",
"      2",
"     </sub>",
"     -blocker while having a syringe of epinephrine (1:1000) at the bedside: I.M., I.V.: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/23/43381?source=see_link\">",
"      see \"Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites (case report of antivenin administration up to 90 hours after bite; O&rsquo;Malley, 1999). However, delayed administration may decrease effectiveness (Edberg, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sensitivity testing:",
"     </b>",
"     Intradermal skin test or conjunctival test may be performed prior to antivenin administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin test: Intradermal: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conjunctival test: Ophthalmic: Instill 1 drop of a 1:100 dilution of normal horse serum into the conjunctival sac",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Desensitization:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"     </b>",
"     <b>",
"      (black widow spider) envenomation; other",
"     </b>",
"     <b>",
"      <i>",
"       Latrodectus",
"      </i>",
"     </b>",
"     <b>",
"      spp envenomation (unlabeled use; Clark, 2001):",
"     </b>",
"     If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H",
"     <sub>",
"      2",
"     </sub>",
"     -blocker while having a syringe of epinephrine (1:1000) at the bedside:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: I.V.: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: I.M., I.V.: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 6000 Antivenin units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer in the anterolateral thigh; apply a tourniquet if an adverse systemic reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer over 15-30 minutes (Clark, 2001); I.V. administration is preferred in severe cases, with shock, or in children &lt;12 years of age. There appears to be no clinical difference in efficacy between the I.M. and I.V. route of administration (Isbister, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with moderate-to-severe symptoms (eg, cramping, intractable pain, hypertension) due to",
"     <i>",
"      Latrodectus mactans",
"     </i>",
"     (black widow spider) envenomation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13331893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with moderate-to-severe symptoms (eg, cramping, intractable pain, hypertension) due to",
"     <i>",
"      Latrodectus",
"     </i>",
"     spp (including",
"     <i>",
"      L. bishopi, L. geometricus, L. hesperus",
"     </i>",
"     , and",
"     <i>",
"      L. variolus",
"     </i>",
"     ) envenomation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash (rare; associated with hypersensitivity reaction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: May be less frequent than described in initial studies (Clark, 2001; Offerman, 2011). One retrospective study reviewed 163 cases of black widow spider envenomation; 58 patients received antivenin therapy and only 1 case of anaphylaxis occurred (Clark, 1992). The risk of reaction appears to be greatest with bolus administration of undiluted antivenin (Clark, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed serum sickness: Delayed serum sickness, albeit uncommon, may occur 1-2 weeks following administration, especially when large doses are used (Clark, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria. All patients require close monitoring in a setting where resuscitation can be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly patients: Due to an increased risk for complications of envenomation, the administration of antivenin may be the preferred initial therapy in patients &gt;60 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thimerosal: Some products may contain thimerosal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Desensitization: A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration (Rojnuckarin, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin/conjunctival  test:  A skin or conjunctival test may be performed prior to use; however, the utility of skin and conjunctival tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (WHO, 2005). One mL of normal horse serum (1:10 dilution) is included for sensitivity testing. The absence of a skin hypersensitivity reaction does not exclude anaphylaxis or hypersensitivity following antivenin administration. False-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Russell, 1979; Sherman, 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; hypersensitivity reactions; serum sickness reaction (for 8-12 days following administration); worsening of symptoms due to envenomation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neutralizes the venom of",
"     <i>",
"      Latrodectus mactans",
"     </i>",
"     (black widow spiders), but may also be effective following envenomation by other",
"     <i>",
"      Latrodectus",
"     </i>",
"     species (including",
"     <i>",
"      L. bishopi, L. geometricus, L. hesperus,",
"     </i>",
"     and",
"     <i>",
"      L. variolus",
"     </i>",
"     ) (Clark, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10180464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 30 minutes; symptoms of envenomation usually subside after 1-3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, &ldquo;The Safety and Efficacy of Antivenin",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2001, 39(2):125-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/11407497/pubmed\" id=\"11407497\" target=\"_blank\">",
"        11407497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, Wethern-Kestner S, Vance MV, et al, &ldquo;Clinical Presentation and Treatment of Black Widow Spider Envenomation: A Review of 163 Cases,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1992, 21(7):782-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/1351707/pubmed\" id=\"1351707\" target=\"_blank\">",
"        1351707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edberg AL, Lanphear JR, Riley BD, et al, &ldquo;Toxic Traveler? Latrodectus Species Envenomation in Michigan With Refractory Symptoms After Antivenin Administration,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2009, 47(4):356-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/19274505/pubmed\" id=\"19274505\" target=\"_blank\">",
"        19274505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handel CC, Izquierdo LA, and Curet LB, &ldquo;Black Widow Spider (",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ) Bite During Pregnancy,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1994, 160(3):261-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/8191768/pubmed\" id=\"8191768\" target=\"_blank\">",
"        8191768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK and Fan HW, &ldquo;Spider Bite,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 378(9808):2039-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/21762981/pubmed\" id=\"21762981\" target=\"_blank\">",
"        21762981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK, Brown SG, Miller M, et al, &ldquo;A Randomised Controlled Trial of Intramuscular vs Intravenous Antivenom for latrodectism-the RAVE Study,&rdquo; QJM, 2008, 101(7):557-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/18400776/pubmed\" id=\"18400776\" target=\"_blank\">",
"        18400776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine M, Canning J, Chase R, et al, &ldquo;Cardiomyopathy Following",
"      <i>",
"       Latrodectus",
"      </i>",
"      Envenomation,&rdquo;",
"      <i>",
"       West J Emerg Med",
"      </i>",
"      , 2010, 11(5):521-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/21293781/pubmed\" id=\"21293781\" target=\"_blank\">",
"        21293781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Offerman SR, Daubert GP, and Clark RF, &ldquo;The Treatment of Black Widow Spider Envenomation With Antivenin",
"      <i>",
"       Latrodectus Mactans",
"      </i>",
"      : A Case Series,&rdquo;",
"      <i>",
"       Permanente J",
"      </i>",
"      , 2011, 15(3):76-81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Malley GF, Dart RC, and Kuffner EF, &ldquo;Successful Treatment of Latrodectism With Antivenin After 90 hours,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(8):657.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/10049091/pubmed\" id=\"10049091\" target=\"_blank\">",
"        10049091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rojnuckarin P, &ldquo;Antivenom Skin Test: Theory Versus Practice,&rdquo;",
"      <i>",
"       Acta Tropica",
"      </i>",
"      , 2009, 109(1):86.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russel FE, Marcus P, and Streng JA, &ldquo;Black Widow Spider Envenomation During Pregnancy: Report of a Case,&rdquo;",
"      <i>",
"       Toxicon",
"      </i>",
"      , 1979, 17(2):188-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/442109/pubmed\" id=\"442109\" target=\"_blank\">",
"        442109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saucier JR, &ldquo;Arachnid Envenomation,&rdquo;",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2004, 22(2):405-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/15163574/pubmed\" id=\"15163574\" target=\"_blank\">",
"        15163574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherman RP, Groll JM, Gonzalez DI, et al, &ldquo;Black Widow Spider (",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ) Envenomation in a Term Pregnancy,&rdquo;",
"      <i>",
"       Curr Surg",
"      </i>",
"      , 2000, 57(4):346-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/12/31941/abstract-text/11024247/pubmed\" id=\"11024247\" target=\"_blank\">",
"        11024247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region,&rdquo; 2005, World Health Organization, Geneva. Available at  file://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8639 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31941=[""].join("\n");
var outline_f31_12_31941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136049\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136038\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136046\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136039\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673200\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673201\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136014\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136029\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136028\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13331893\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136047\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136018\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298765\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136022\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136041\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136025\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136017\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10180464\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/36/21059?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/23/43381?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_12_31942="Tarantula";
var content_f31_12_31942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tarantula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard S Vetter, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31942=[""].join("\n");
var outline_f31_12_31942=null;
var title_f31_12_31943="Cardiac abnormalities in children and adolescents with systemic lupus erythematosus";
var content_f31_12_31943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31943/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/12/31943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis is the most common cardiac abnormality in children with SLE, but other problems such as myocarditis, valvular disease, and coronary artery disease can occur. Cardiac abnormalities in children with SLE are often silent.",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of potential cardiac abnormalities in children and adolescents with SLE will be reviewed here. An overview of the clinical manifestations and treatment of SLE and the cardiac manifestations of neonatal lupus erythematosus are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3289305\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of clinical heart disease among children with systemic lupus erythematosus (SLE) ranges in various studies from 12 to 54 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. Subclinical disease, detected by echocardiography or found in autopsy studies, also occurs in many children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In one study, an echocardiogram was performed on 40 subjects whose charts were reviewed for frequency of cardiac abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/9\">",
"     9",
"    </a>",
"    ]. Sixty-eight percent of subjects (27 of 40) had abnormalities, which were persistent in 5 of 14 subjects who had a second echocardiogram. Three of the five subjects were found to have moderately severe cardiac defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERICARDIAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis may be the cause of recurrent nonspecific chest pain and should be sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis is common in children with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/3\">",
"     3",
"    </a>",
"    ] and clinically significant in nearly one quarter. The classic presentation is an acute, sharp, anterior chest pain, often accompanied by dyspnea. Inspiration exacerbates the pain, which may be alleviated by an upright forward leaning position. The differential diagnosis of pericarditis must include pulmonary embolism and also the remote possibility of myocardial infarction.",
"   </p>",
"   <p>",
"    On physical examination, low-grade fever, tachycardia, and tachypnea are commonly present. A pericardial rub also may be heard. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large pericardial effusions may accumulate without symptoms until they cause cardiac tamponade. These children present with symptoms suggestive of heart failure and accompanied by findings of distant heart sounds, pulsus paradoxus, hepatomegaly, and jugular venous distention. The diagnosis is suggested by enlargement of the cardiac silhouette on chest radiographs (ie, water bottle-shaped heart) and confirmed by echocardiography. Although cardiac tamponade is rare in children, it may be the initial manifestation of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Constrictive pericarditis typically follows repeated episodes of chest pain in childhood SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/17\">",
"     17",
"    </a>",
"    ]. Severe cases may require surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=see_link\">",
"     \"Recurrent pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When pericardial fluid is withdrawn, either to relieve pressure or exclude infection, antinuclear antibodies and immune complexes typical of lupus may be found in the sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/18\">",
"     18",
"    </a>",
"    ]. The glucose concentration should be normal but the protein concentration can vary. Pericardial histopathology demonstrates foci of inflammation that are usually composed predominantly of mononuclear cells. Scarring may be prominent in recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pericarditis is suspected from the history and physical examination. ST-T wave changes on electrocardiogram (EKG) may also suggest the diagnosis. Echocardiography is an effective, non-invasive method of documenting the presence of fluid around the heart. However, it may not be diagnostic in certain cases, such as those marked by small posterior pericardial effusions, or by pericardial inflammation with minimal fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with rapid accumulation of large pericardial effusions may develop tamponade and require prompt pericardiocentesis. In contrast, asymptomatic patients may not require specific therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic pericarditis may be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Large doses of glucocorticoids are rarely necessary, but in the setting of severe constrictive pericarditis, pulse doses of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, not to exceed 1 g) may be used acutely. Indothemacin (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in two doses) or other NSAIDs are often effective in milder cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activity is self-restricted during acute episodes of pericarditis because of the pain. Clinical status should be monitored by follow-up echocardiography, and activities may be resumed as is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MYOCARDIAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical myocardial disease is documented at autopsy more commonly than would be expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/7,21-23\">",
"     7,21-23",
"    </a>",
"    ], but clinically significant myocarditis is rare in children with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentations of myocarditis are varied in nature and severity (",
"    <a class=\"graphic graphic_table graphicRef66776 \" href=\"mobipreview.htm?12/25/12699\">",
"     table 1",
"    </a>",
"    ). At onset, myocarditis may manifest as tachycardia. Worsening myocarditis may be evidenced by gallop rhythm, murmur, arrhythmia, pulmonic congestion, or hepatomegaly. Electrocardiographic findings are nonspecific and may include decreased voltages and inverted T waves. Myocarditis is best diagnosed and evaluated by echocardiography, which typically shows evidence of decreased myocardial contractility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant myocarditis in children and adolescents with SLE typically is treated with glucocorticoids, usually in the form of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . The dose of prednisone is decreased as the patient responds to therapy. Activity should be restricted as appropriate to the compromise in cardiac function determined by echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     VALVULAR HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic cardiac lesion of Libman-Sacks endocarditis (described below) was present in one-half (7 of 14) of patients in an autopsy study from 1960 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in subsequent studies, the lesions were less frequently found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Echocardiographic evaluation of children with SLE during the last decade suggests valvular lesions in childhood SLE are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/9,10,23,24\">",
"     9,10,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granular, vegetative lesions are typically present on the surfaces or edges of the valves in patients with Libman-Sacks endocarditis. They also may be found on the chordae tendinae, papillary muscles, and the atrial or ventricular walls (",
"    <a class=\"graphic graphic_picture graphicRef79709 \" href=\"mobipreview.htm?37/6/37984\">",
"     picture 1",
"    </a>",
"    ). The lesions are composed of mononuclear cells, fibrin, and platelet thrombi. A major complication is infection and subsequent subacute bacterial endocarditis.",
"   </p>",
"   <p>",
"    The relevance of antiphospholipid antibodies to the development of cardiac valve disease is controversial, although a strong association between autoantibodies and both valvulitis and Libman-Sacks endocarditis has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Antibodies to SS-A (Ro) and SS-B (La) also have been reported to be associated with higher frequency of valvular disease in children with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/8\">",
"     8",
"    </a>",
"    ]. These may represent concordant findings in more severe disease rather than pathogenic association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Libman-Sacks endocarditis may or may not have a clinically significant or changing murmur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/28\">",
"     28",
"    </a>",
"    ]. Because infective endocarditis can develop in asymptomatic patients, blood cultures and echocardiography should be performed whenever a new or changing murmur is noted in a patient with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/19,29-31\">",
"     19,29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with a prior history of infective endocarditis should receive antibiotic prophylaxis as recommended by the American Heart Association when undergoing procedures with a risk of bacteremia. Periodic echocardiography provides the best assessment of valvular function over time and helps determine whether further intervention is needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SLE have an increased risk for early atherosclerosis and coronary artery disease (CAD) that may not become clinically apparent until they are young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/32\">",
"     32",
"    </a>",
"    ]. In one study, 5 of 40 children with SLE (30 females; mean age 15.9 years) without symptoms or history of ischemic heart disease had abnormal coronary perfusion when evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/10\">",
"     10",
"    </a>",
"    ]. Total plaque burden correlates with lupus disease duration, low vitamin D levels, and failure to use ACE inhibitors in African American patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/33\">",
"     33",
"    </a>",
"    ]. CAD directly impacts on the long-term prognosis of children with SLE. Prolonged use of moderate to high dose glucocorticoids is considered the predominant risk factor for CAD in children with SLE by many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, there have been contrary reports regarding the relative role of the disease itself versus glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/36\">",
"     36",
"    </a>",
"    ]. Nonetheless the use of glucocorticoids is a known risk factor for myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link&amp;anchor=H19#H19\">",
"     \"Systemic lupus erythematosus in children\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a variety of possible explanations for the increased prevalence of CAD in children with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/2,4,38-40\">",
"     2,4,38-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevation of serum lipids is common at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/41\">",
"       41",
"      </a>",
"      ] and persists because of active disease or corticosteroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. Dyslipidemia contributes to accelerated arteriosclerosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=see_link&amp;anchor=H7#H7\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Dyslipidemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=see_link&amp;anchor=H235228225#H235228225\">",
"       \"Definition and screening for dyslipidemia in children\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammation may affect the coronary arteries directly.",
"     </li>",
"     <li>",
"      Systemic hypertension, another common feature of SLE, may affect the coronary arteries indirectly.",
"     </li>",
"     <li>",
"      Lymphopenia, which occurs in about two-thirds of patients with SLE, is associated with progressive carotid intima-media wall thickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/46\">",
"       46",
"      </a>",
"      ]. The absence of a clear mechanism for this association suggests that lymphopenia may be a surrogate marker for disease activity. However, an association between lymphopenia and SLEDAI scores was not seen. Thus, the basis of this association remains unresolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first recognized manifestation of coronary artery disease in children with SLE is often myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/23,38,39,47\">",
"     23,38,39,47",
"    </a>",
"    ]. Improved control of the acute inflammatory manifestations of SLE has dramatically improved life expectancy.",
"   </p>",
"   <p>",
"    Children with SLE presenting with severe chest pain must be evaluated for the possibility of myocardial infarction. However, the majority of children with CAD are asymptomatic. Echocardiography and necropsy studies reveal CAD in a significant number of adolescents with SLE without prior physical or historical evidence of CAD. Although most chest pain in children with SLE is caused by pleuritis or pericarditis, other causes such as CAD or pulmonary emboli must be considered in the differential diagnosis because of their potentially grave consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42534?source=see_link\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a scientific statement from the American Heart Association (AHA), eight disease conditions including chronic inflammatory diseases (eg, SLE) associated with an increased risk of CAD were identified and classified based upon their risk for CVD (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). Chronic inflammatory diseases (eg, SLE) were determined to be associated with a moderate increase in risk for CAD based upon this three-tier disease risk stratification schema for premature CAD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=see_link&amp;anchor=H8#H8\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Chronic inflammatory diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for reducing the risk of CAD are based upon risk assessment and the presence of other CAD risk factors, such as hypertension. Suggested therapeutic interventions include nonpharmacologic measures (eg, low-saturated-fat, low-cholesterol diet and routine exercise) and pharmacologic measures including statins and antihypertensive medications, as needed. However, a study of the use of statins in children with SLE found that their routine use was not justified.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21432?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    was not significantly more effective than placebo in preventing subclinical atherosclerosis progression, as measured by carotid intima-media thickening, in a 36 month randomized trial of 221 patients aged 10 to 21 with pediatric-onset SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/0/40965?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    , a treatment recommended for children with SLE, can improve lipid profiles and minimize the likelihood of a disease flare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/45\">",
"     45",
"    </a>",
"    ]. Management to reduce the risk of atherosclerosis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure in children with SLE is usually the result of renal or pulmonary compromise (eg, hypertension, glomerulonephritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrosis, and pulmonary disease) rather than intrinsic cardiac disease.",
"   </p>",
"   <p>",
"    Treatment must address the underlying comorbid conditions while supporting the myocardium appropriately. Angiotensin converting enzyme inhibitors should be used where appropriate because they are not only effective antihypertensives but have antithrombotic and antiatherogenic actions as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31943/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/56/11138?source=see_link\">",
"       \"Patient information: Pericarditis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac disease, often subclinical, commonly occurs in children with systemic lupus erythematosus (SLE). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3289305\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardial disease is the most common cardiac abnormality in children with SLE. It typically presents as a sharp, anterior chest pain. The diagnosis is confirmed by echocardiography. Cardiac tamponade due to large pericardial effusion is a rare but life-threatening complication, which may require fluid removal by pericardiocentesis. Corticosteroid therapy is the usual medical treatment for symptomatic pericarditis. Nonsteroidal anti-inflammatory drugs (NSAIDs) may help prevent recurrent disease or permit lower doses of corticosteroid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pericardial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocardial disease varies in severity in affected children with SLE. It may be symptomatic (eg, persistent tachycardia) but is more commonly asymptomatic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Myocardial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less common cardiac abnormalities in children with SLE include valvular heart disease and infective endocarditis, coronary artery disease, and heart failure. In particular, children with SLE are at risk for premature atherosclerosis as adults because of an increased risk of dyslipidemia, hypertension, and vasculitis of the coronary arteries. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Valvular heart disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Coronary artery disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Heart failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/1\">",
"      King KK, Kornreich HK, Bernstein BH, et al. The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum 1977; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/2\">",
"      Fish AJ, Blau EB, Westberg NG, et al. Systemic lupus erythematosus within the first two decades of life. Am J Med 1977; 62:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/3\">",
"      Caeiro F, Michielson FM, Bernstein R, et al. Systemic lupus erythematosus in childhood. Ann Rheum Dis 1981; 40:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/4\">",
"      Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.",
"     </a>",
"    </li>",
"    <li>",
"     Jacobs JC. Pediatric rheumatology for the practitioner, Springer-Verlag, New York 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/6\">",
"      Buoncompagni A, Barbano GC, Pistoia V, et al. Childhood systemic lupus erythematosus: a review of 30 cases. Clin Exp Rheumatol 1991; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/7\">",
"      COOK CD, WEDGWOOD RJ, CRAIG JM, et al. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 1960; 26:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/8\">",
"      Oshiro AC, Derbes SJ, Stopa AR, Gedalia A. Anti-Ro/SS-A and anti-La/SS-B antibodies associated with cardiac involvement in childhood systemic lupus erythematosus. Ann Rheum Dis 1997; 56:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/9\">",
"      Al-Abbad AJ, Cabral DA, Sanatani S, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001; 10:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/10\">",
"      Gazarian M, Feldman BM, Benson LN, et al. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr 1998; 132:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/11\">",
"      Panchal L, Divate S, Vaideeswar P, Pandit SP. Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 patients in India. J Postgrad Med 2006; 52:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/12\">",
"      Gulati S, Kumar L. Cardiac tamponade as an initial manifestation of systemic lupus erythematosus in early childhood. Ann Rheum Dis 1992; 51:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/13\">",
"      Lerer RJ. Cardiac tamponade as an initial finding in systemic lupus erythematosus. Am J Dis Child 1972; 124:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/14\">",
"      Tamura A, Agematsu K, Urasawa R, et al. Cardiac tamponade due to systemic lupus erythematosus in a 7-year-old boy with selective IgG subclass deficiency. Eur J Pediatr 1998; 157:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/15\">",
"      Malci�� I, Seneci�� I, Dasovi�� A, Radoni�� M. [Incipient pericardial tamponade as the first symptom of systemic lupus erythematosus in 2 children]. Reumatizam 1995; 42:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/16\">",
"      Aiuto LT, Stambouly JJ, Boxer RA. Cardiac tamponade in an adolescent female: an unusual manifestation of systemic lupus erythematosus. Clin Pediatr (Phila) 1993; 32:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/17\">",
"      Jacobson EJ, Reza MJ. Constrictive pericarditis in systemic lupus erythematosus. Demonstration of immunoglobulins in the pericardium. Arthritis Rheum 1978; 21:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/18\">",
"      Hunder GG, Mullen BJ, McDuffie FC. Complement in pericardial fluid of lupus erythematosus. Studies in two patients. Ann Intern Med 1974; 80:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/19\">",
"      Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/20\">",
"      De Inocencio J, Lovell DJ. Cardiac function in systemic lupus erythematosus. J Rheumatol 1994; 21:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/21\">",
"      Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985; 110:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/22\">",
"      Strauer BE, Brune I, Schenk H, et al. Lupus cardiomyopathy: cardiac mechanics, hemodynamics, and coronary blood flow in uncomplicated systemic lupus erythematosus. Am Heart J 1976; 92:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/23\">",
"      Guevara JP, Clark BJ, Athreya BH. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. J Rheumatol 2001; 28:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/24\">",
"      Norris DG, Col&oacute;n AR, Stickler GB. Systemic lupus erythematosus in children: the complex problems of diagnosis and treatment encountered in 101 such patients at the Mayo Clinic. Clin Pediatr (Phila) 1977; 16:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/25\">",
"      Kaplan SD, Chartash EK, Pizzarello RA, Furie RA. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992; 124:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/26\">",
"      Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006; 54:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/27\">",
"      Moyssakis I, Tektonidou MG, Vasilliou VA, et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007; 120:636.",
"     </a>",
"    </li>",
"    <li>",
"     Petty RE, Cassidy JT. Systemic lupus erythematosus. In: Textbook of pediatric rheumatology, 4th ed, Cassidy JT, Petty RE (Eds), WB Saunders Company, Philadelphia 2001. p.396.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/29\">",
"      Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/30\">",
"      Roldan CA. Valvular disease associated with systemic illness. Cardiol Clin 1998; 16:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/31\">",
"      Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992; 20:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/32\">",
"      Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/33\">",
"      Ravenell RL, Kamen DL, Spence JD, et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci 2012; 344:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/34\">",
"      Sturfelt G, Eskilsson J, Nived O, et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients form a defined population. Medicine (Baltimore) 1992; 71:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/35\">",
"      Bj&ouml;rn&aring;dal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/36\">",
"      Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/37\">",
"      Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011; 33:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/38\">",
"      Ishikawa S, Segar WE, Gilbert EF, et al. Myocardial infarct in a child with systemic lupus erythematosus. Am J Dis Child 1978; 132:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/39\">",
"      Friedman DM, Lazarus HM, Fierman AH. Acute myocardial infarction in pediatric systemic lupus erythematosus. J Pediatr 1990; 117:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/40\">",
"      Spiera H, Rothenberg RR. Myocardial infarction in four young patients with SLE. J Rheumatol 1983; 10:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/41\">",
"      Tyrrell PN, Beyene J, Benseler SM, et al. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol 2007; 34:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/42\">",
"      Sarkissian T, Beyenne J, Feldman B, et al. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 2006; 54:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/43\">",
"      Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/44\">",
"      Sarkissian T, Beyene J, Feldman B, et al. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007; 56:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/45\">",
"      Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007; 16:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/46\">",
"      Huang YL, Chung HT, Chang CJ, et al. Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2009; 60:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/47\">",
"      Englund JA, Lucas RV Jr. Cardiac complications in children with systemic lupus erythematosus. Pediatrics 1983; 72:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/48\">",
"      Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012; 64:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31943/abstract/49\">",
"      Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6427 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31943=[""].join("\n");
var outline_f31_12_31943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3289305\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERICARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MYOCARDIAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      VALVULAR HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CORONARY ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6427|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6427|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/6/37984\" title=\"picture 1\">",
"      Verrucous endocarditis in SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6427|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/25/12699\" title=\"table 1\">",
"      Clinical features of myocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/56/11138?source=related_link\">",
"      Patient information: Pericarditis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_12_31944="Hepatocyte transplantation";
var content_f31_12_31944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatocyte transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31944/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/12/31944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the understanding of hepatocyte engraftment and the remarkable proliferative potential of hepatocytes have brought liver cell transplantation to the doorstep of application in the treatment of inherited and acquired human diseases. Extensive animal experiments have shown that hepatocytes transplanted in the liver or at ectopic sites survive, function, and participate in the regenerative process. Because the host liver architecture remains intact following the integration of the engrafted hepatocytes in the liver cords, hepatocyte transplantation is metabolically less stressful than transplantation of the whole organ, and the consequences of graft loss are much less severe.",
"   </p>",
"   <p>",
"    Hepatocyte transplantation has many potential applications. Therapeutic genes can be transferred into cultured hepatocytes, and the phenotypically modified cells can be then transplanted for ex vivo gene therapy. Such gene transfer could be used to replace a missing gene product or to prevent immune rejection. Gene therapy of the host is also being explored for prevention of rejection of allografted or xenografted hepatocytes. Hepatocyte transplantation does not interfere with subsequent liver transplantation or gene therapy. Although the clinical efficacy of hepatocyte transplantation has been demonstrated, the shortage of good quality donor livers for hepatocyte isolation and the lack of dependable methods of cryopreservation will limit widespread clinical application of this method until further research overcomes these problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCOPE OF HEPATOCYTE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, hepatocyte transplantation has many potential clinical applications (",
"    <a class=\"graphic graphic_table graphicRef74795 \" href=\"mobipreview.htm?22/26/22955\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment of inherited metabolic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missing gene products can be substituted by transplanting normal primary hepatocytes from allogeneic donors. This simple approach holds promise for diseases such as Crigler-Najjar syndrome type 1, ornithine transcarbamylase deficiency, and hemophilia. In addition, gene therapy can aid in abolishing or decreasing immune response against allografts or xenografts and promote repopulation of transplanted cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=see_link\">",
"     \"Crigler-Najjar syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=see_link&amp;anchor=H6#H6\">",
"     \"Inborn errors of metabolism: Classification\", section on 'Urea cycle disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33878?source=see_link\">",
"     \"Genetics of the hemophilias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatocytes used for gene therapy can be derived from a separate donor (allogeneic transplantation) or the recipient (autologous transplantation). An advantage of autologous transplantation is that it does not require immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management of acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver cell transplantation can assist in the management of patients with fulminant hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The transplanted hepatocytes can provide temporary liver support in patients awaiting the availability of a donor liver or spontaneous recovery. In some patients, regeneration of endogenous hepatocytes combined with the transplanted hepatocytes could possibly replace the need for transplantation of the whole liver. Whether this approach is superior to the use of artificial liver assist devices remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=see_link&amp;anchor=H233808218#H233808218\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Artificial hepatic assist devices and hepatocyte transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management of chronic liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocyte transplantation can provide metabolic support and partially restore liver function in patients with chronic liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/7\">",
"     7",
"    </a>",
"    ]. Transplanted normal hepatocytes have a survival advantage compared with the host cells in some inherited disorders, such as hereditary tyrosinemia type I (fumarylacetoacetate hydrolase deficiency), and may repopulate the liver over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    .) Similarly, transplanted hepatocytes can massively repopulate the liver in settings in which host hepatocytes have been prevented from undergoing normal regeneration because of chemical or radiation-induced damage of their DNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SOURCES OF HEPATOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal experiments, primary hepatocytes derived from congenic (varying in only one gene locus) or syngeneic (immunologically compatible) strains can be transplanted without the need for immunosuppression. Such complete tissue matching is not possible in clinical situations. As mentioned above, when hepatocytes are used as vehicles for ex vivo gene therapy, immunosuppression can be circumvented by isolating hepatocytes from resected liver segments and transplanting them back to the donor after genetic manipulations. However, in most cases, the cells are obtained from allogeneic donors and immunosuppression will be required, unless specific tolerance to the alloantigens can be achieved (see below).",
"   </p>",
"   <p>",
"    The worldwide shortage of donor organs severely limits the number of donor livers that can be used for hepatocyte isolation. This has led to the search for alternative sources of hepatocytes. A number of alternatives to primary hepatocytes are being explored for hepatocyte transplantation, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immortalized hepatocytes: Hepatocytes derived from animal and human livers have been immortalized by transferring the gene for the large T antigen of the simian virus 40 (SV40). A potential problem with this approach is that while the T antigen alone does not result in malignant transformation of hepatocytes, it predisposes to transformation by oncogenes, such as Ras. As a result, for transplantation purposes, methods for conditional immortalization of hepatocytes are being sought [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/9\">",
"       9",
"      </a>",
"      ]. One such approach (developed in rat hepatocytes) involves transfer of a gene for a thermolabile mutant T antigen into hepatocytes using retroviral vectors. The transduced cells proliferate in vitro at permissive temperatures (33&ordm;C). However, at physiologic temperatures (37 to 39&ordm;C), the mutant T antigen is degraded, thereby stopping cell growth and leading the cells to exhibit features of differentiated hepatocytes. In rodent models, conditionally immortalized hepatocytes have been used to provide metabolic support in acute or chronic liver failure, and for ex vivo gene therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More recently, methods utilizing the",
"      <span class=\"nowrap\">",
"       p-lox/cre",
"      </span>",
"      recombinase system have been used to reversibly immortalize hepatocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/10\">",
"       10",
"      </a>",
"      ]. Human hepatocytes, conditionally immortalized in this manner, were used successfully to rescue rats with acute liver failure, induced by 90 percent hepatectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Xenogeneic hepatocytes: Hepatocytes derived from porcine or other animal sources could be potentially used for providing metabolic support during liver failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/12\">",
"       12",
"      </a>",
"      ], but major immunological hurdles remain. Another concern about these approaches is the potential to transmit agents, such as the porcine endogenous retroviruses, which can infect humans.",
"     </li>",
"     <li>",
"      Fetal hepatocytes: Human fetal hepatocytes have been transplanted into patients with acute liver failure with marginal benefit. More recently, transplantation of EpCAM+ve liver progenitor cells isolated from human fetal liver by infusion into the hepatic artery of patients with decompensated cirrhosis was reported to improve synthetic and excretory functions of the liver [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatocytes derived from pluripotent cells: Several laboratories have developed methods to generate hepatocyte-like cells by in vitro differentiation of human embryonic stem cells or induced pluripotent stem cells produced by reprogramming of somatic cells, such as fibroblasts and blood cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. Such cells could be potentially renewable sources of hepatocytes, suitable for transplantation, provided the safety and regulatory issues could be addressed adequately.",
"     </li>",
"     <li>",
"      Adult",
"      <span class=\"nowrap\">",
"       stem/progenitor",
"      </span>",
"      cells: Cells that can self replicate as well as differentiate into multiple cell types persist in many adult tissues, including the bone marrow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/17\">",
"       17",
"      </a>",
"      ], fat, and the liver. In animal studies, transplanted bone marrow-derived cells have been shown to give rise to hepatocytes, albeit at a very low frequency, making it questionable whether they could be a significant source of hepatocytes for transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/18\">",
"       18",
"      </a>",
"      ]. Mesenchymal stem cells derived from human adipose tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/19\">",
"       19",
"      </a>",
"      ] and mouse tail fibroblasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/20\">",
"       20",
"      </a>",
"      ] have been differentiated into cells exhibiting some characteristics of hepatocytes. Benefits of using such cells for the treatment of liver-based disorders have yet to be demonstrated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SITES OF HEPATOCYTE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver provides the most supportive environment for engraftment and function of transplanted hepatocytes because of the availability of nutrients and growth factors present in the portal circulation, and interaction with other liver cells and the hepatic matrix. However, the optimum route for hepatocyte transplantation also depends upon the specific application.",
"   </p>",
"   <p>",
"    Hepatocytes infused into the portal vein or injected into the splenic pulp travel to the hepatic sinusoids and integrate into the liver cords [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The cells obtain polarity and establish appropriate junctions with the neighboring hepatocytes within 24 hours. Studies in rats, mice, and rabbits have shown that syngeneic or congenic hepatocytes survive and function throughout the life of the host. Hepatocytes equivalent to up to 5 percent of the liver mass could be transplanted into normal livers with only a transient and reversible increase in the portal pressure. By contrast, hepatocyte transplantation in cirrhotic animals results in portal hypertension and an increase in right atrial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After injection into the splenic pulp, a fraction of the transplanted cells may survive in the spleen and eventually develop liver cord-like structures, replacing up to 40 percent of the splenic mass. Over time, bile canaliculi, sinusoids, and endothelial cells may develop. Thus, in specific circumstances, the spleen may serve as an important site of hepatocyte engraftment.",
"   </p>",
"   <p>",
"    For inherited metabolic disorders, implantation into the liver via injection into a tributary of the portal vein or into the splenic pulp has been most effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, the liver may not be the most desirable site for hepatocyte transplantation in settings in which the hepatic architecture is distorted (such as cirrhosis). Although hepatocytes can engraft within cirrhotic nodules, it is doubtful that the transplanted cells will function normally in this environment. Similarly, a liver that is undergoing massive necrosis may not provide a hospitable environment for the transplanted cells. In the presence of portal hypertension, a large proportion of the cells infused into the portal vein may be translocated to the pulmonary vascular bed. In such cases, hepatocytes have been transplanted into the spleen by injection into the splenic pulp or infusion into the splenic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. More study is needed to determine if the transplantation in the splenic artery would augment liver function in patients with liver cirrhosis.",
"   </p>",
"   <p>",
"    Other sites, such as the renal subcapsular space or subcutaneous tissue, are less efficient. However, with further development, the peritoneal cavity could be an effective site for transplanting hepatocytes that are encapsulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/27\">",
"     27",
"    </a>",
"    ], attached to collagen-coated microcarriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/28\">",
"     28",
"    </a>",
"    ], or encased in Hydrogel-based hollow fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRECLINICAL EVALUATION IN EXPERIMENTAL ANIMAL MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of hepatocyte transplantation has been evaluated extensively in natural mutant animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Animal models of disorders due to single gene defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocytes have been transplanted into Gunn rats (a model of Crigler-Najjar syndrome type 1), which have life-long unconjugated hyperbilirubinemia due to the lack of hepatic bilirubin-UDP-glucuronosyltransferase activity, by infusion into the portal vein, injection into the splenic pulp, or attachment to microcarriers, followed by injection into the peritoneal cavity. These procedures resulted in the excretion of bilirubin glucuronides in the bile and amelioration of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The metabolic defect was corrected in subsequent studies in which the rats were first treated with liver resection and radiation, thereby promoting the preferential repopulation of the native liver with the transplanted hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/32\">",
"     32",
"    </a>",
"    ]. Hepatic irradiation appears to disrupt hepatic sinusoidal endothelial cells and inhibit the phagocytic function of Kupffer cells, thereby enhancing hepatocyte engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, serum albumin levels increased after transplantation of normal hepatocytes into Nagase analbuminemic rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/34\">",
"     34",
"    </a>",
"    ]. Hepatocyte transplantation reduced plasma cholesterol levels by up to 50 percent in Watanabe heritable hyperlipidemic rabbits that lack LDL receptors (an animal model of familial hypercholesterolemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/35\">",
"     35",
"    </a>",
"    ]. Hepatocyte transplantation also ameliorates the metabolic abnormality in fumarylacetoacetate hydrolase deficient mice (a model of hereditary tyrosinemia 1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/8\">",
"     8",
"    </a>",
"    ], Long-Evans Cinnamon rats (a model of Wilson's disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/36\">",
"     36",
"    </a>",
"    ], and mdr2",
"    <span class=\"nowrap\">",
"     (-/-)",
"    </span>",
"    mice (a model of progressive familial intrahepatic cholestasis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23624?source=see_link&amp;anchor=H4#H4\">",
"     \"Disorders of tyrosine metabolism\", section on 'Hereditary tyrosinemia type 1'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=see_link&amp;anchor=H20#H20\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Familial hepatocellular cholestasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Animal models of acute and chronic liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation of hepatocytes significantly improved the survival of animals with acute liver failure induced by D-galactosamine or dimethylnitrosamine administration, hepatic ischemia, or 90 percent hepatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/28,38\">",
"     28,38",
"    </a>",
"    ], but not in a mouse model of acute toxic liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/39\">",
"     39",
"    </a>",
"    ]. Hepatocyte transplantation reversed encephalopathy and prevented intracranial hypertension in animals with ischemic liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/40\">",
"     40",
"    </a>",
"    ]. In rats with hepatic encephalopathy caused by end-to-side portacaval shunt, intrasplenic transplantation of hepatocytes improved the behavior score, partially corrected amino acid imbalances, and protected the rats from hepatic coma induced by an exogenous ammonia load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/40\">",
"     40",
"    </a>",
"    ]. In similar experiments, transplantation of hepatocytes that had been immortalized by transfection with the simian virus 40 T antigen was able to improve measures of liver failure and prolong survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/41\">",
"     41",
"    </a>",
"    ]. Hepatocyte transplantation in rats with chronic decompensated liver cirrhosis stabilized total bilirubin and prothrombin time, improved serum albumin and encephalopathy scores, and prolonged survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Massive repopulation of the liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of hepatocyte transplantation could be greatly enhanced if the transplanted cells could be induced to proliferate preferentially over the host hepatocytes. Hepatocytes have a great reserve regenerative capacity. However, because there are normal physiologic mechanisms that tend to keep the total hepatocyte mass constant, replacement of the host liver cells with transplanted hepatocytes requires a combination of proliferative stimuli to the hepatocytes and impairment of the ability of host hepatocytes to divide.",
"   </p>",
"   <p>",
"    This combination exists naturally in urokinase plasminogen activator transgenic mice (uPA). In these animals, the host hepatocytes have a markedly reduced life span, and therefore, transplanted normal hepatocytes proliferate preferentially, until the whole liver is replaced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/42\">",
"     42",
"    </a>",
"    ]. A similar situation exists in FAH-deficient mouse models of hereditary tyrosinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/43\">",
"     43",
"    </a>",
"    ] and MDR3 gene knockout deficient mice (model of progressive intrahepatic cholestasis type 3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/44\">",
"     44",
"    </a>",
"    ]. However, severe liver injury or markedly reduced hepatocyte life-span is not always necessary for hepatic repopulation with transplanted cells. In a transgenic mouse model of the classic form of human alpha-1 antitrypsin disease (AAT-ZZ), transplanted normal hepatocytes were shown to spontaneously proliferate and replace the host hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/45\">",
"     45",
"    </a>",
"    ]. As in the case of a majority of human AAT-ZZ patients, liver injury is minimal in these mice, but the stress of production of the misfolded protein (AAT-Z) is sufficient to provide a competitive proliferative advantage to the engrafted normal hepatocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For more generalized application of these principles, chemical and physical devices are being explored for inhibiting the proliferation of host hepatocytes. In one approach, the recipient was treated with a DNA-modifying agent, retrorsine, followed by partial hepatectomy and hepatocyte transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/46\">",
"     46",
"    </a>",
"    ]. The transplanted cells progressively replaced the host liver. An alternative strategy uses preparative resection and irradiation of the host liver. Using this method, it has been possible to replace the host hepatocytes almost entirely with normal transplanted hepatocytes, while retaining the normal hepatic architecture and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/6\">",
"     6",
"    </a>",
"    ]. Application of this procedure in Gunn rats resulted in complete normalization of serum bilirubin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/32,47\">",
"     32,47",
"    </a>",
"    ]. None of these procedures has been evaluated in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ex vivo gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocytes can be transduced in vitro and then transplanted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one report, for example, primary hepatocytes from LDL-receptor deficient Watanabe heritable hyperlipidemic rabbits were harvested and transduced with a recombinant virus expressing the LDL receptor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/48\">",
"     48",
"    </a>",
"    ]. The transduced hepatocytes were then transplanted back into the rabbits. Long-term expression of the transgene was observed and the serum cholesterol levels were reduced by 20 to 30 percent during several months of observation. A clinical trial of this method in human subjects with familial hypercholesterolemia resulted in modest reduction of serum LDL cholesterol levels, which were not considered to be therapeutically useful.",
"   </p>",
"   <p>",
"    At this time, several factors limit the efficiency of ex vivo gene therapy for liver diseases. The procedure requires partial hepatectomy and, as a result, cannot be repeated easily. The proportion of primary hepatocytes that can be established in culture and transduced using recombinant viral vectors remains modest and variable. The number of phenotypically corrected hepatocytes that can be harvested and engrafted after transplantation also restricts the final metabolic impact of ex vivo gene therapy. Solutions to these technical problems may come from improved hepatocyte culture methods and conditional immortalization of hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/9\">",
"     9",
"    </a>",
"    ]. However, because of the current hurdles, ex vivo gene therapy for liver diseases is unlikely to be applied broadly in the near future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with hepatocyte transplantation in humans is growing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatocyte transplantation for metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients have undergone hepatocyte transplantation for a variety of conditions, including alpha-1 antitrypsin deficiency, Crigler-Najjar syndrome type 1, coagulation Factor VII deficiency, glycogen storage disease, infantile Refsum's disease, and progressive familial intrahepatic cholestasis (",
"    <a class=\"graphic graphic_table graphicRef67880 \" href=\"mobipreview.htm?2/11/2238\">",
"     table 2",
"    </a>",
"    ). The results have been variable because of differences in the severity of the underlying diseases, the quality and quantity of transplanted hepatocytes, and immune rejection of the transplants.",
"   </p>",
"   <p>",
"    For example, one child with the urea cycle disorder ornithine transcarbamylase deficiency (OTC) received 10 billion hepatocytes. Although some clinical improvement was seen, she died of pneumonia a short time later. A newborn OTC deficient child who received hepatocyte transplantation via the umbilical vein had normalization of plasma ammonia and glutamine levels on normal diet without",
"    <span class=\"nowrap\">",
"     phenylbutyrate/phenylacetate",
"    </span>",
"    therapy. However, following repeated transplantation from multiple donors, the cells appeared to be rejected, possibly because of inadequate immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One 18-week-old child received hepatocyte transplantation for alpha-1 antitrypsin deficiency, but the patient had to be subsequently treated with orthotopic liver transplantation as the liver biopsy of the patient at the time of cell transplantation revealed cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term therapeutic benefit of hepatocyte transplantation was demonstrated unequivocally in a 10-year-old patient with Crigler-Najjar syndrome type 1 who received 7.5 billion hepatocytes via a percutaneous portal vein catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/52\">",
"     52",
"    </a>",
"    ]. Duodenal bile samples collected at various time points up to two years showed the excretion of significant amounts of bilirubin monoglucuronide and diglucuronide, demonstrating function of the engrafted hepatocytes in vivo. Hepatic bilirubin-UDP-glucuronosyltransferase activity was also detected on liver biopsy specimens (5.5 percent of the normal compared to 0.4 percent before treatment). Serum bilirubin declined from a pretreatment average of 27",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to around 11 to 13",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and the phototherapy could be reduced from 12 to 6",
"    <span class=\"nowrap\">",
"     hr/day.",
"    </span>",
"    It appears that transplantation of a larger number of hepatocytes or some maneuver to promote preferential proliferation of the transplanted cells (see above) would be required for complete cure of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatocyte transplantation for liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the efficacy of transplanted cells can be best evaluated in the treatment of inherited metabolic disorders, the greatest need for hepatocyte transplantation is for acute and chronic liver failure. In an early study, hepatocytes were injected into the spleen of several patients with chronic hepatitis and cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/25\">",
"     25",
"    </a>",
"    ]. Epidermal growth factor was injected into the splenic artery to stimulate hepatocyte proliferation. The transplanted hepatocytes were detected in 88 percent of patients 1 to 11 months after transplantation, although the metabolic benefit was not clear.",
"   </p>",
"   <p>",
"    Another group injected 5 billion pooled human fetal (24- to 34-week gestation) hepatocytes into the peritoneal cavity of patients with fulminant hepatic failure (FHF) of less than two weeks in duration and grade III-IV encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/53\">",
"     53",
"    </a>",
"    ]. More patients who received the transplanted cells survived (48 versus 33 percent), but the difference was not statistically significant because of the small number of patients. Best results were obtained when the transplantation was performed during earlier stages of liver failure. In the survivors, plasma ammonia and serum bilirubin levels decreased in 48 hours after hepatocyte transplantation.",
"   </p>",
"   <p>",
"    In the United States, hepatocyte transplantation has been performed in an effort to \"bridge\" patients awaiting orthotopic liver transplantation (OLT) for FHF or chronic liver failure with acute decompensation (",
"    <a class=\"graphic graphic_table graphicRef70376 \" href=\"mobipreview.htm?35/48/36620\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69654 \" href=\"mobipreview.htm?15/16/15631\">",
"     table 4",
"    </a>",
"    ). Following transplantation by infusion into the splenic artery, 66 percent of patients with FHF survived long enough to receive OLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/54\">",
"     54",
"    </a>",
"    ]. In the patients with chronic failure with acute decompensation, only one of four survived long enough to receive OLT. In the transplant recipients, there was improvement in plasma ammonia levels, grade of encephalopathy, cerebral perfusion pressure, and prothrombin time, but the differences from the values observed in controls were not statistically significant. Because most survivors had received OLT, it is difficult to be sure whether hepatocyte transplantation provided a significant clinical benefit. However, in one 37-year-old woman with HBV induced liver failure, there was sufficient recovery after hepatocyte transplantation to permit discharge from the hospital without OLT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepatocyte transplantation for ex vivo gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ex vivo gene therapy has been performed in patients with familial hypercholesterolemia (LDL receptor deficiency). Hepatocytes were isolated by collagenase perfusion of resected liver segments from patients. The cells were transduced with LDL receptor gene in culture using retroviral vectors, and were transplanted back into the donors. Although persistence of the transgene expression was demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/48\">",
"     48",
"    </a>",
"    ], the serum cholesterol reduction was modest and probably not therapeutically beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EXISTING HURDLES AND CURRENT RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the major barrier to extensive clinical application of hepatocyte transplantation is the shortage of donor organs for hepatocyte isolation. Hepatocytes are usually obtained from donor organs that have been rejected for transplantation because of extensive steatosis. Cells obtained from these livers are of variable viability and their survival after cryopreservation is unpredictable. The best quality hepatocytes are obtained from segmental transplants or reduced liver grafts, which have the shortest duration of cold-ischemia.",
"   </p>",
"   <p>",
"    Although the experience is limited, it appears that repeated cell transplantation from multiple donors may increase the possibility of allograft rejection. Development of reliable methods of cryopreservation of human hepatocytes will be needed for repeated transplantation of hepatocytes obtained from a single donor. A study in fumaryl acetoacetate dehydrogenase-deficient mice (model of hereditary tyrosinemia) demonstrated that adult human hepatocytes, like adult rodent hepatocytes, retain the capacity to proliferate extensively and massively repopulate the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/56\">",
"     56",
"    </a>",
"    ]. In some disorders, such as the classic form of alpha1 antitrypsin (AAT) deficiency, accumulation of the mutant AAT-Z protein in hepatocytes causes a stress in the host liver that promotes spontaneous repopulation by transplanted normal hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/45\">",
"     45",
"    </a>",
"    ]. However, in a majority of liver-based inherited metabolic disorders, the longevity and regenerative capacity of host hepatocytes remains normal. In these cases, an alternative solution could be to prepare the host liver to promote repopulation by a relatively small number of transplanted hepatocytes. The use of preparative irradiation of the host liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/6,47,57\">",
"     6,47,57",
"    </a>",
"    ] or treatment of the host with drugs (eg, retrorsine) that suppress host hepatocyte proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/46\">",
"     46",
"    </a>",
"    ] have been evaluated in preclinical studies for enhancing the engraftment and preferential proliferation of the transplanted cells. Segmental repopulation of the liver by regiospecific hepatic irradiation is currently under clinical trial at the University of Pittsburgh.",
"   </p>",
"   <p>",
"    Alternative sources of hepatocytes are also being explored. Research on culture and transplantation of fetal hepatocytes is in its infancy, but offers great possibilities. As mentioned above, conditionally immortalized human hepatocytes, from which the immortalizing gene (eg, SV-40 large T antigen) can be deleted prior to transplantation, have been developed and are being evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/9\">",
"     9",
"    </a>",
"    ]. Transplantation of hepatocytes from xenogeneic sources is also being explored, although major immunological barriers and the risk of infection of human tissues by known or unknown animal viruses are important concerns.",
"   </p>",
"   <p>",
"    A noninvasive method to measure the mass of engrafted cells could greatly facilitate the follow-up and optimization of hepatocyte transplantation methods. One way to accomplish this is to mark cells genetically before transplantation. Luciferase-based optical imaging, which is effective in mouse experiments, is not applicable to humans because of the greater thickness of the abdominal wall. However, magnetic resonance imaging methods are being developed for three-dimensional quantification of transplanted hepatocytes using genetic marking with creatinine phosphokinase, which is not normally expressed in hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatocyte transplantation would be much more useful and attractive if the need for immunosuppression could be circumvented. For this purpose, the immunoresponse of the host to specific alloantigens could be abrogated by interference with costimulation between antigen presenting cells and cytotoxic lymphocytes, at the time of hepatocyte transplantation, by the administration of CTLA4-Ig alone, or in combination with an anti-CD40 antibody. CTLA4-Ig could also be expressed in vivo by gene transfer for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As an alternative, immunomodulatory genes could be transduced into the donor hepatocytes before transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/2\">",
"     2",
"    </a>",
"    ]. Some studies in rodents showed that ex vivo transduction with some viral genes can protect transplanted liver cells from allograft rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31944/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocyte transplantation has many potential clinical applications (",
"    <a class=\"graphic graphic_table graphicRef74795 \" href=\"mobipreview.htm?22/26/22955\">",
"     table 1",
"    </a>",
"    ). Although the clinical application of hepatocyte transplantation has begun already, concerted efforts by many investigators will be needed to overcome the current technical hurdles before this promising therapeutic modality receives wider application. The major barrier to extensive clinical application of hepatocyte transplantation is the shortage of donor organs for hepatocyte isolation. A clinical trial is underway for evaluating preparative methods for enhancing the engraftment and proliferation of transplanted hepatocytes. Hepatocyte transplantation would also be much more useful and attractive if the need for immunosuppression could be circumvented.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/1\">",
"      Benedetti E, Kirby JP, Asolati M, et al. Intrasplenic hepatocyte allotransplantation in dalmation dogs with and without cyclosporine immunosuppression. Transplantation 1997; 63:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/2\">",
"      Ilan Y, Sauter B, Roy-Chowdhury N, et al. Expression of adenoviral E3 gene production in normal rat hepatocytes prevents their rejection upon transplantation into allogeneic Gunn rats (abstract). Hepatology 1997; 26:490A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/3\">",
"      Fabrega AJ, Bommineni VR, Blanchard J, et al. Amelioration of analbuminemia by transplantation of allogeneic hepatocytes in tolerized rats. Transplantation 1995; 59:1362.",
"     </a>",
"    </li>",
"    <li>",
"     Fox IJ, Roy Chowdhury N, Roy Chowdhury J. Hepatocyte transplantation in liver failure and inherited metabolic disorders. In: Acute Liver Failure, Lee WM, Williams R (Eds), Cambridge University Press, UK 1997. p.285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/5\">",
"      Roger V, Balladur P, Honiger J, et al. Internal bioartificial liver with xenogeneic hepatocytes prevents death from acute liver failure: an experimental study. Ann Surg 1998; 228:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/6\">",
"      Guha C, Sharma A, Gupta S, et al. Amelioration of radiation-induced liver damage in partially hepatectomized rats by hepatocyte transplantation. Cancer Res 1999; 59:5871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/7\">",
"      Kobayashi N, Ito M, Nakamura J, et al. Hepatocyte transplantation improves liver function and prolongs survival in rats with decompensated liver cirrhosis. Transplant Proc 1999; 31:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/8\">",
"      Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996; 12:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/9\">",
"      Fox IJ, Chowdhury NR, Gupta S, et al. Conditional immortalization of Gunn rat hepatocytes: an ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer. Hepatology 1995; 21:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/10\">",
"      Paillard F. Reversible cell immortalization with the Cre-lox system. Hum Gene Ther 1999; 10:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/11\">",
"      Kobayashi N, Fujiwara T, Westerman KA, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000; 287:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/12\">",
"      Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995; 92:4942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/13\">",
"      Khan AA, Shaik MV, Parveen N, et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant 2010; 19:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/14\">",
"      Basma H, Soto-Guti&eacute;rrez A, Yannam GR, et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 2009; 136:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/15\">",
"      Loh YH, Agarwal S, Park IH, et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113:5476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/16\">",
"      Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/17\">",
"      Lagasse E, Connors H, Al-Dhalimy M, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/18\">",
"      Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006; 43:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/19\">",
"      Aurich H, Sgodda M, Kaltwasser P, et al. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 2009; 58:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/20\">",
"      Huang P, He Z, Ji S, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/21\">",
"      Gupta S, Aragona E, Vemuru RP, et al. Permanent engraftment and function of hepatocytes delivered to the liver: implications for gene therapy and liver repopulation. Hepatology 1991; 14:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/22\">",
"      Gupta S, Rajvanshi P, Lee CD. Integration of transplanted hepatocytes into host liver plates demonstrated with dipeptidyl peptidase IV-deficient rats. Proc Natl Acad Sci U S A 1995; 92:5860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/23\">",
"      Gupta S, Yerneni PR, Vemuru RP, et al. Studies on the safety of intrasplenic hepatocyte transplantation: relevance to ex vivo gene therapy and liver repopulation in acute hepatic failure. Hum Gene Ther 1993; 4:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/24\">",
"      Ponder KP, Gupta S, Leland F, et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci U S A 1991; 88:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/25\">",
"      Kusano M, Mito M. Observations on the fine structure of long-survived isolated hepatocytes inoculated into rat spleen. Gastroenterology 1982; 82:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/26\">",
"      Holzman MD, Rozga J, Neuzil DF, et al. Selective intraportal hepatocyte transplantation in analbuminemic and Gunn rats. Transplantation 1993; 55:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/27\">",
"      Dixit V, Arthur M, Reinhardt R, Gitnick G. Improved function of microencapsulated hepatocytes in a hybrid bioartificial liver support system. Artif Organs 1992; 16:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/28\">",
"      Demetriou AA, Reisner A, Sanchez J, et al. Transplantation of microcarrier-attached hepatocytes into 90% partially hepatectomized rats. Hepatology 1988; 8:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/29\">",
"      Honiger J, Balladur P, Mariani P, et al. Permeability and biocompatibility of a new hydrogel used for encapsulation of hepatocytes. Biomaterials 1995; 16:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/30\">",
"      Matas AJ, Sutherland DE, Steffes MW, et al. Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science 1976; 192:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/31\">",
"      Groth CG, Arborgh B, Bj&ouml;rk&eacute;n C, et al. Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte transplantation. Transplant Proc 1977; 9:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/32\">",
"      Guha C, Parashar B, Deb NJ, et al. Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection. Hepatology 2002; 36:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/33\">",
"      Yamanouchi K, Zhou H, Roy-Chowdhury N, et al. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology 2009; 49:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/34\">",
"      Rozga J, Holzman M, Moscioni AD, et al. Repeated intraportal hepatocyte transplantation in analbuminemic rats. Cell Transplant 1995; 4:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/35\">",
"      Gunsalus JR, Brady DA, Coulter SM, et al. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. Nat Med 1997; 3:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/36\">",
"      Yoshida Y, Tokusashi Y, Lee GH, Ogawa K. Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans cinnamon rats. Gastroenterology 1996; 111:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/37\">",
"      De Vree JM, Ottenhoff R, Bosma PJ, et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/38\">",
"      Baumgartner D, LaPlante-O'Neill PM, Sutherland DE, Najarian JS. Effects of intrasplenic injection of hepatocytes, hepatocyte fragments and hepatocyte culture supernatants on D-galactosamine-induced liver failure in rats. Eur Surg Res 1983; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/39\">",
"      Braun KM, Degen JL, Sandgren EP. Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells. Nat Med 2000; 6:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/40\">",
"      Ribeiro J, Nordlinger B, Ballet F, et al. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacaval-shunted rats. Hepatology 1992; 15:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/41\">",
"      Cai J, Ito M, Nagata H, et al. Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. Hepatology 2002; 36:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/42\">",
"      Petersen J, Dandri M, Gupta S, Rogler CE. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1998; 95:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/43\">",
"      Overturf K, Al-Dhalimy M, Manning K, et al. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. Hum Gene Ther 1998; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/44\">",
"      De Vree, JM, Ottenhoff, R, Smith, AJ, et al. Rapid correction of Mdr 2 deficiency by transplantation of MDR3 transgenic hepatocytes. Hepatology Supp 1998; 28:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/45\">",
"      Ding J, Yannam GR, Roy-Chowdhury N, et al. Spontaneous hepatic repopulation in transgenic mice expressing mutant human &alpha;1-antitrypsin by wild-type donor hepatocytes. J Clin Invest 2011; 121:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/46\">",
"      Laconi E, Oren R, Mukhopadhyay DK, et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol 1998; 153:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/47\">",
"      Guha C, Parashar B, Roy Chowdhury N, et al. Complete, long-term normalization of serum bilirubin levels in Gunn rats after hepatocyte transplantation following partial hepatectomy and liver irradiation. Hepatology Supp 1999; 30:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/48\">",
"      Chowdhury JR, Grossman M, Gupta S, et al. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/49\">",
"      Oertel M, Rosencrantz R, Chen YQ, et al. Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. Hepatology 2003; 37:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/50\">",
"      Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/51\">",
"      Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc 1997; 29:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/52\">",
"      Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/53\">",
"      Habibullah CM, Syed IH, Qamar A, Taher-Uz Z. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/54\">",
"      Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/55\">",
"      Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/56\">",
"      Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007; 25:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/57\">",
"      Zhou H, Dong X, Kabarriti R, et al. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PLoS One 2012; 7:e46775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/58\">",
"      Landis CS, Yamanouchi K, Zhou H, et al. Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P MRS imaging in mice. Hepatology 2006; 44:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/59\">",
"      Hathcock KS, Laszlo G, Dickler HB, et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/60\">",
"      Wallace PM, Rodgers JN, Leytze GM, et al. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J Immunol 1995; 154:5885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31944/abstract/61\">",
"      Mashalova EV, Guha C, Roy-Chowdhury N, et al. Prevention of hepatocyte allograft rejection in rats by transferring adenoviral early region 3 genes into donor cells. Hepatology 2007; 45:755.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4593 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31944=[""].join("\n");
var outline_f31_12_31944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCOPE OF HEPATOCYTE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment of inherited metabolic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management of acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management of chronic liver failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SOURCES OF HEPATOCYTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SITES OF HEPATOCYTE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRECLINICAL EVALUATION IN EXPERIMENTAL ANIMAL MODELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Animal models of disorders due to single gene defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Animal models of acute and chronic liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Massive repopulation of the liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ex vivo gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatocyte transplantation for metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatocyte transplantation for liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatocyte transplantation for ex vivo gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EXISTING HURDLES AND CURRENT RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/26/22955\" title=\"table 1\">",
"      Hepatocyte transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2238\" title=\"table 2\">",
"      Inherited metabolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/48/36620\" title=\"table 3\">",
"      Chronic liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/16/15631\" title=\"table 4\">",
"      Acute liver failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6201?source=related_link\">",
"      Crigler-Najjar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33878?source=related_link\">",
"      Genetics of the hemophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_12_31945="Ulceration in amebic colitis";
var content_f31_12_31945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulceration in amebic colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Gross pathology of amebic colitis showing multiple ulcer formation.",
"    <br>",
"     (B) Classic flask-shaped ulcer of amebiasis. Mucosal ulceration with widespread submucosal invasion shown.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: the Centers for Disease Control and Prevention and Drs. Mae Melvin and E West.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31945=[""].join("\n");
var outline_f31_12_31945=null;
var title_f31_12_31946="Geriatric nutrition: Nutritional issues in older adults";
var content_f31_12_31946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Geriatric nutrition: Nutritional issues in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Christine Ritchie, MD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/12/31946/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/12/31946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes associated with normal aging increase nutritional risk for older adults. Aging is characterized by diminished organ system reserves, weakened homeostatic controls, and increased heterogeneity among individuals, influenced by genetic and environmental factors.",
"   </p>",
"   <p>",
"    Nutritional needs of the older individual are determined by multiple factors, including specific health problems and related organ system compromise; an individual's level of activity, energy expenditure, and caloric requirements; the ability to access, prepare, ingest, and digest food; and personal food preferences.",
"   </p>",
"   <p>",
"    This topic will discuss assessment of nutrition in the older adult, as well as the etiology, evaluation, and treatment of weight loss, overnutrition, and specific common nutrient deficiencies. Related issues of geriatric health maintenance and nutritional assessment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=see_link\">",
"     \"Geriatric health maintenance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=see_link\">",
"     \"Approach to the patient with weight loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23175?source=see_link\">",
"     \"Dietary and nutritional assessment in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING FOR NUTRITIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from studies of acute hospitalization in older patients suggest that up to 71 percent are at nutritional risk or are malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/1\">",
"     1",
"    </a>",
"    ]. Malnutrition is associated with increased mortality risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/2\">",
"     2",
"    </a>",
"    ]. The following criteria for the diagnosis of malnutrition have been recommended in a consensus statement from the Academy of Nutrition and Dietetics (Academy) and the American Society for Parenteral and Enteral Nutrition (ASPEN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Two or more of the following six characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient energy intake",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Loss of muscle mass",
"     </li>",
"     <li>",
"      Loss of subcutaneous fat",
"     </li>",
"     <li>",
"      Localized or generalized fluid accumulation that may mask weight loss",
"     </li>",
"     <li>",
"      Diminished functional status as measured by handgrip strength.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial measurements of body weight offer the simplest screen for nutritional adequacy and change in nutritional status in older adults.",
"   </p>",
"   <p>",
"    Obtaining periodic body weights may be challenging, particularly in frail patients. A chair or bed scale that is regularly calibrated may be needed for patients who cannot stand on an upright balance beam scale. Low body weight is defined as &lt;80 percent of the recommended body weight (",
"    <a class=\"graphic graphic_table graphicRef53284 \" href=\"mobipreview.htm?23/10/23724\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that weight loss in older adults, especially if it is not volitional, is predictive of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. Loss of as little as 5 percent of weight over a three year period is associated with increased mortality among community-dwelling older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss for those with a BMI below 30 likely poses a greater mortality threat to older adults than not losing weight or of having a BMI of 25 to 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/7\">",
"     7",
"    </a>",
"    ]. However, obesity (BMI &ge;30) continues to have a negative impact on morbidity and mortality in older adults. The relative benefit of intentional weight loss in obese older adults with osteoarthritis, impaired activity tolerance, diabetes mellitus, and coronary heart disease, especially when combined with exercise, is becoming increasingly apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss is considered to be clinically significant with the following parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ge;2 percent decrease of baseline body weight in one month",
"     </li>",
"     <li>",
"      &ge;5 percent decrease in three months, or",
"     </li>",
"     <li>",
"      &ge;10 percent in six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the long term care setting, a clinically significant weight loss episode is defined by the long term care Minimum Data Set (MDS) as loss of 5 percent of usual body weight in 30 days, or 10 percent in 6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Screening tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of screening tools have been developed for identifying older adults at risk for poor nutrition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Nutritional Risk Screening (NRS) 2002 has two components: a screening assessment for undernutrition and an estimate for disease severity. Undernutrition is estimated with three variables: BMI, percent recent weight loss, and change in food intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/13\">",
"       13",
"      </a>",
"      ]. Disease severity ranges from a score of zero (for those with chronic illnesses or a hip fracture) to three (for those in the ICU with an APACHE score of 10). In hospitalized patients, the NRS 2002 showed a sensitivity of 39 to 70 percent and a specificity of 83 to 93 percent when compared to the Mini Nutritional Assessment and the Subjective Global Assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Simplified Nutrition Assessment Questionnaire (SNAQ), a four item screener, was tested in community-dwelling older adults and long-term care residents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/15\">",
"       15",
"      </a>",
"      ]. In those populations, it had a sensitivity and specificity of 88.2 and 83.5 percent, respectively, for identification of older persons at risk for 5 and 10 percent weight loss, respectively (",
"      <a class=\"graphic graphic_figure graphicRef71772 \" href=\"mobipreview.htm?36/4/36943\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      SCREEN II (Seniors in the Community: Risk Evaluation for Eating and Nutrition) is a 17-item tool that assesses nutritional risk by evaluating food intake, physiological barriers to eating (difficulty with chewing or swallowing), weight change, and",
"      <span class=\"nowrap\">",
"       social/functional",
"      </span>",
"      barriers to eating. The tool has excellent sensitivity and specificity, as well as interrater and",
"      <span class=\"nowrap\">",
"       test/retest",
"      </span>",
"      reliability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/16\">",
"       16",
"      </a>",
"      ]. An eight-question abbreviated version of SCREEN II is also available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Malnutrition Universal Screening Tool (MUST) incorporates BMI, weight loss in three to six months, and anorexia for five days due to disease. It is commonly used in the United Kingdom and is particularly sensitive for recognition of protein energy undernutrition in hospitalized patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Malnutrition Screening Tool (MST) was developed for use in acutely hospitalized patients and also validated for use in cancer patients (average age 57 to 60 years, range 15 to 89) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/19\">",
"       19",
"      </a>",
"      ]. It asks two simple questions: &ldquo;Have you been eating poorly because of a decreased appetite?&rdquo; and &ldquo;Have you lost weight recently without trying?&rdquo; The sensitivity of the MST in hospitalized patients ranges from 74 to 100 percent with a specificity of 76 to 93 percent when compared to the Subjective Global Assessment.",
"     </li>",
"     <li>",
"      The Mini Nutritional Assessment (MNA) consists of a global assessment and subjective perception of health, as well as questions specific to diet, and a series of anthropomorphic measurements (",
"      <a class=\"graphic graphic_figure graphicRef79831 \" href=\"mobipreview.htm?5/35/5685\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/20\">",
"       20",
"      </a>",
"      ]. It has been widely validated and is predictive of poor outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. The",
"      <a class=\"external\" href=\"file://www.health.vic.gov.au/older/toolkit/05Nutrition/docs/Mini Nutrition Assessment Short Form (MNA-SF).pdf\">",
"       Mini Nutritional Assessment-Short Form",
"      </a>",
"      uses six questions from the full MNA and can substitute calf circumference if BMI is not available. A validation study demonstrated good sensitivity compared to the full MNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two screening tools in the highest quartile for sensitivity (&gt;83 percent) and specificity (&gt;90 percent) were the MNA (SF) and the MST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UNDERNUTRITION SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of malnutrition in older adults is dependent upon the population studied, varying by geography, age distribution, and living situation. A review of results of the Mini Nutritional Assessment across settings and countries in Europe, the United States and South Africa, found the prevalence of malnutrition among 4507 people (mean age 82.3, 75.2 percent female) was 22.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/25\">",
"     25",
"    </a>",
"    ]. Highest rates were in the rehabilitation setting (50.5 percent) and lowest among community dwellers (5.8 percent). Over a third of hospitalized older adults (38.7 percent) in this study met the criteria for malnutrition.",
"   </p>",
"   <p>",
"    Compared to younger adults, undernutrition in older individuals is both more common and may have greater impact on outcomes, including physical function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/26\">",
"     26",
"    </a>",
"    ], healthcare utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/27\">",
"     27",
"    </a>",
"    ], and length of stay for surgical hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/28\">",
"     28",
"    </a>",
"    ]. Inadequate energy intake is common in hospitalized older adults, with increased risk associated with poor appetite, higher BMI, diagnosis of infection or cancer, delirium, and need for assistance with feeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/29\">",
"     29",
"    </a>",
"    ]. Some studies suggest that older adults are less able to adapt to underfeeding. One study found that, following a period of experimental underfeeding, older adults experienced less frequent hunger than younger adults, and did not regain the total amount of weight they had lost when allowed to consume food freely for six months while on average younger adults regained all their lost weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast, a similar study did not demonstrate age differences in ad libitum intake, anthropometric indices, gastric emptying rate, and cholecystokinin levels in blood after a period of underfeeding and then consumption of food freely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of ability to compensate for periods of low food intake due to illness or other difficulties can result in long-term, persistent weight changes, especially when combined with social, medical, or psychological factors that can negatively impact body weight.",
"   </p>",
"   <p>",
"    Involuntary weight loss is driven by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate dietary intake",
"     </li>",
"     <li>",
"      Appetite loss (anorexia)",
"     </li>",
"     <li>",
"      Disuse or muscle atrophy (sarcopenia)",
"     </li>",
"     <li>",
"      Inflammatory effects of disease (cachexia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    or a combination of these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inadequate dietary intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of weight loss due to inadequate nutrient intake. These include social (eg, poverty, isolation), psychological (eg, depression, dementia), medical (eg, edentulism, dysphagia), and pharmacological issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Social factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social factors contributing to weight loss include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased likelihood of isolation at mealtimes. One third of persons over 65, and half over 85 live alone, which typically decreases food enjoyment and calorie intake. Several studies have demonstrated that older adults who eat in the presence of others consume more than those who eat alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Financial limitations affecting food acquisition. A greater proportion of older adults live near the poverty line, compared to the general population. Individuals with fixed incomes may use money previously spent on food for medications and other needed items.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Medical and psychiatric factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important medical and psychiatric causes of weight loss in older adults are malignancy and depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy was identified as the cause for weight loss in 9 percent of older patients in a study of medical outpatients, and was second to depression as the most frequent identifiable cause of undernutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/34\">",
"       34",
"      </a>",
"      ]. In another study of unexplained weight loss in 45 ambulatory older adults, the most common identified cause for weight loss was depression (18 percent), again followed by malignancy (16 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/35\">",
"       35",
"      </a>",
"      ]. A third report found cancer, predominantly of the gastrointestinal tract, as a cause of weight loss in 36 percent of the 154 patients evaluated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression and dysphoria are common in older adults and often remain unrecognized and undertreated. Depression is an important cause of weight loss in the subacute care and nursing home settings, as well as in older patients in the community. In a chart review of 1017 medical outpatients, for example, depression was the cause of weight loss in 30 percent of the older patients, compared to only 15 percent in younger patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"       \"Diagnosis and management of late-life depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysphagia is present in approximately 7 to 10 percent of the older adult population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/37\">",
"     37",
"    </a>",
"    ] and has a negative effect on energy intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/38\">",
"     38",
"    </a>",
"    ]. Dysphagia occurs in about one half of patients with acute first-ever stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/39\">",
"     39",
"    </a>",
"    ] or with Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/40\">",
"     40",
"    </a>",
"    ]. Oropharyngeal dysphagia may occur due to stroke, Parkinson disease, amyotrophic lateral sclerosis, Zenker's diverticula, and other motility or structural disorders. Esophageal dysphagia can be due to motility problems (eg, achalasia, diffuse esophageal spasm, scleroderma) and structural issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important medical etiologies to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine disorders (hyperthyroidism, new onset diabetes mellitus)",
"     </li>",
"     <li>",
"      End organ disease (congestive heart failure, end stage renal disease, chronic obstructive pulmonary disease, hepatic failure)",
"     </li>",
"     <li>",
"      Gastrointestinal disorders (celiac disease, ischemic bowel, inflammatory bowel disease, pancreatic insufficiency, peptic ulcer disease, GERD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infections (tuberculosis)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatologic disorders (polymyalgia rheumatica, rheumatoid arthritis)",
"     </li>",
"     <li>",
"      Neurological conditions (Parkinson disease, chronic pain)",
"     </li>",
"     <li>",
"      Alzheimer's disease (especially among those with behavioral and psychological symptoms) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Drug or alcohol dependence",
"     </li>",
"     <li>",
"      Medication side effects (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , opioids, serotonin-reuptake inhibitors, diuretics, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, medical or dental conditions in older adults may impair the ability to eat. Paralysis from stroke, severe arthritis, hand tremors, and dementia may lead to routine need for feeding assistance from others.",
"   </p>",
"   <p>",
"    Chewing difficulty puts older adults at risk for poor intake. In a study of non-institutionalized older adults, edentulousness doubled the risk for significant weight loss over a one-year period, after adjusting for gender, income, age, and baseline weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Physiologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic factors associated with weight loss include age-related decrease in taste and smell sensitivity, delayed gastric emptying, early satiety, and impairment in the regulation of food intake.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age raises the threshold for odor detection and lowers perceived odor intensity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/43\">",
"       43",
"      </a>",
"      ]. The number of taste buds remains constant, but thresholds for recognition of salt and other specific tastes increase. Impaired taste and smell likely alter the cephalic phase of digestion, affecting learned associations between the taste and smell of food with signals involved in meal initiation, volume of food intake, and meal termination.",
"     </li>",
"     <li>",
"      Decrease in the rate of gastric emptying in older adults may result in prolonged antral distension with reduced hunger and increased satiety [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aging may influence production of,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CNS sensitivity to, several digestive hormones thought to be involved in satiety. Glucagon, glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), leptin, and ghrelin are peripheral satiety signals and appear to be less well detected by the brain with increased age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Causes of impaired regulation of food intake include decreased stimulatory effects of neurotransmitters involved in appetite (eg, opioids, neuropeptide Y, the orexins and ghrelin) and increased sensitivity to the inhibitory effects of corticotropin-releasing factor, serotonin, and cholecystokinin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anorexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia, the decrease in appetite, in older adults is influenced by multiple physiological changes. Food intake gradually diminishes with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Much of the intake reduction in early old age is an appropriate response to decreased energy needs due to reduced physical activity, decreased resting energy expenditure (REE),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of lean body mass.",
"   </p>",
"   <p>",
"    Changes in taste and smell lead to a decreased desire to eat and early satiety develops with age, related to gastrointestinal changes and gastric hormone changes, as discussed above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Physiologic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Appetite regulation is further affected by illness, drugs, dementia, and mood disorders. In 292 older adults from assisted living facilities or senior centers, fair to poor emotional well-being was most closely associated with poor appetite (OR 5.60, 95% CI 2.60-12.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cachexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cachexia has been defined as a \"complex metabolic syndrome associated with underlying illness, and characterized by loss of muscle with or without loss of fat mass\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/49\">",
"     49",
"    </a>",
"    ]. It is associated with increased morbidity. Anorexia, inflammation, insulin resistance, and increased muscle protein breakdown are frequently associated with cachexia.",
"   </p>",
"   <p>",
"    Cachexia is distinct from starvation, age-related loss of muscle mass (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Sarcopenia'",
"    </a>",
"    below), or psychiatric, intestinal, or endocrinologic causes of weight loss. Cachexia involves many dysregulated pathways, leading to an imbalance between catabolism and anabolism. Because of the presence of underlying inflammation and catabolism, cachexia often is resistant to nutritional intervention.",
"   </p>",
"   <p>",
"    Cachexia usually occurs in the setting of underlying illness involving a cytokine-mediated response. Such illnesses include cancer, end-stage renal disease, chronic pulmonary disease, congestive heart failure, rheumatoid arthritis, and AIDS.",
"   </p>",
"   <p>",
"    Pro-inflammatory cytokines commonly involved in cachexia include interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These cytokines contribute to lipolysis, muscle protein breakdown, and nitrogen loss, in addition to producing anorexia. They augment the acute phase response, up-regulate the production of C-reactive protein and down-regulate the transcription of albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of older Framingham Heart Study participants, levels of insulin-like growth factor 1 (IGF-1) and muscle mass decreased, whereas interleukin 6 levels increased, with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/53\">",
"     53",
"    </a>",
"    ]. These changes appear to occur even in the absence of overt disease, suggesting that a subclinical inflammatory process may be part of normal aging. Although elevated pro-inflammatory cytokines (especially IL-1, IL-6 and TNF-a) are commonly seen in older adults, levels are higher in those with cachexia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sarcopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcopenia is a syndrome characterized by the loss of muscle mass, strength, and performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Low muscle mass is defined as a decrease in appendicular muscle mass two standard deviations below the mean for young healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/57\">",
"     57",
"    </a>",
"    ], and is usually measured by DEXA or bio-electrical impedance in clinical practice. Unlike cachexia, sarcopenia does not require the presence of an underlying illness. Also, whereas most people with cachexia are sarcopenic, most sarcopenic individuals are not considered cachectic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/58\">",
"     58",
"    </a>",
"    ]. Sarcopenia is associated with increased rates of functional impairment, disability, falls and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/59\">",
"     59",
"    </a>",
"    ]. The causes of sarcopenia are multifactorial and can include disuse, changing endocrine function, chronic diseases, inflammation, insulin resistance, and nutritional deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sarcopenia was identified in 53 to 57 percent of men, and 43 to 60 percent of women, over the age of 80 in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/60\">",
"     60",
"    </a>",
"    ]. Loss of muscle mass, accompanied by decreased muscle strength, can occur in overweight individuals (sarcopenic-obese) as well as in normal and underweight individuals.",
"   </p>",
"   <p>",
"    Causes of sarcopenia include endocrine changes, activation of proinflammatory cytokines, reduced alpha motor units in the spinal cord, decreased physical activity, and suboptimal protein intake.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reductions in testosterone and estrogen that accompany aging appear to accelerate the development of sarcopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/61\">",
"       61",
"      </a>",
"      ]. Relative deficiencies of estrogen and testosterone contribute to muscle catabolism and promotion of catabolic cytokines such as IL-1 and IL-6 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/30\">",
"       30",
"      </a>",
"      ]. Testosterone replacement may increase muscle mass, but studies have not demonstrated similar benefit for estrogen replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/62-64\">",
"       62-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insulin resistance increases with age. Insulin inhibits muscle breakdown and the reduction of insulin action on muscle may contribute to muscle catabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical activity declines with age. In the United States, 28 to 34 percent of adults aged 65 to 74 and 35 to 44 percent of adults ages 75 or older are inactive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/66\">",
"       66",
"      </a>",
"      ]. Inactivity exacerbates ongoing muscle loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/67\">",
"       67",
"      </a>",
"      ] and increases proportion of body fat mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadequate protein intake can also contribute to sarcopenia. In a small randomized study of postmenopausal women, consumption of inadequate dietary protein (0.45",
"      <span class=\"nowrap\">",
"       g/kg/d)",
"      </span>",
"      compared to adequate intake (0.92",
"      <span class=\"nowrap\">",
"       g/kg/d)",
"      </span>",
"      for six weeks led to deterioration in strength and lean body mass. In one US survey, more than 10 percent of adults over age 60 in the US consumed less than the current RDA for protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study in the United Kingdom of 2983 men and women aged 59 to 73 years found an independent correlation between increased grip strength and consumption of fatty fish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/70\">",
"     70",
"    </a>",
"    ]. The speculation is raised that the anti-inflammatory properties of omega-3-fatty acids may be a factor in prevention of sarcopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION OF WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations vary on the degree of weight loss, and the period of time for weight loss, that should prompt clinical investigation. One commonly accepted definition for clinically important weight loss is loss of 4 to 5 percent of total body weight over 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/2\">",
"     2",
"    </a>",
"    ]. Unintentional weight loss should lead to clinical concern regardless of whether the patient is overweight at baseline. Whether or not intentional weight loss is of concern remains a matter of some speculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following steps are suggested in the initial evaluation of an older person who is noted to have lost weight, or for whom concern is raised about weight loss by the patient, family members, or caregivers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Document the weight loss. While it is important to note objective evidence of weight loss from recorded serial weights over time, this information is often not available.",
"      <br/>",
"      <br/>",
"      Body fat and lean muscle mass may be estimated using bioelectrical impedance or anthropometric measures such as mean upper arm circumference (MUAC) or mid-arm circumference. MUAC measures the circumference of the left upper arm at the mid-point between the tip of the shoulder and the tip of the elbow (olecranon process and the acromium). MUAC of less than 22 cm for women and 23 cm for men are suggestive of chronic energy deficiency. Although suggestive of malnutrition, it is unclear whether MUAC predicts mortality and morbidity. The MUST screening tool and the MNA both use mid-arm circumference measures as part of their assessment.",
"      <br/>",
"      <br/>",
"      Bioelectrical impedance measures are available for use with wheelchair bound and bedbound patients, although bioelectrical impedance is significantly influenced by hydration status.",
"     </li>",
"     <li>",
"      Evaluate appetite and dietary intake. Determining if there has been a change in hunger and satiety may provide more clinically revealing information than performing a formal dietary recall. Patients should be questioned regarding appetite, their dietary intake in relation to their usual pattern, the number of meals they consume per day, portion size, snacks between meals, if and when they feel full during their meal, and whether the patient likes what he or she is eating. The SGA, MNA, and SNAQ all evaluate aspects of dietary intake in this way (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening tools'",
"      </a>",
"      above). A more formal dietary intake assessment can be obtained with a dietetic consult.",
"     </li>",
"     <li>",
"      Perform a complete history and physical examination, and order appropriate laboratory studies. As a baseline, we suggest laboratory evaluation for evidence of metabolic or inflammatory disease, to include a basic chemistry profile including glucose and electrolytes, TSH, complete blood count (CBC), and CRP if cachexia is suspected. Chest and plain abdomen radiographs may be considered. Although studies describing the causes of IVL have routinely performed chest x-rays and abdominal films, there is no clear evidence of their value. Order addition studies based on suspicion of underlying disease from the patient's history and examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Those with no localizing findings and with normal complete blood count, biochemical profile, or chest and plain abdomen radiographs have been considered by some to have isolated involuntary weight loss (IIVL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/71\">",
"     71",
"    </a>",
"    ]. In one series, a little more than one-third of patients with IIVL were ultimately diagnosed with a malignancy. Multivariate analysis found the strongest predictors of neoplasm in the setting of IIVL were age &gt;80 years, white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;12,000/mm3,",
"    </span>",
"    serum albumin &lt;3.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    serum alkaline phosphatase &gt; 300",
"    <span class=\"nowrap\">",
"     UI/L,",
"    </span>",
"    and serum lactate dehydrogenase (LDH) &gt;500",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    These authors recommend CBC, ESR, serum albumin, liver function studies, LDH, and abdominal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Subsequent evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear guidelines for how to proceed in the assessment of a patient with weight loss and negative initial findings. The diagnostic yield of a",
"    <span class=\"nowrap\">",
"     thoracic/abdominal/pelvic",
"    </span>",
"    CT examination to assess for occult or metastatic malignant disease has not been determined. Incidental findings are common, the studies are costly, and may be inappropriate in patients who are frail or who have multiple comorbidities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of evidence-based recommendations, we suggest ordering a",
"      <span class=\"nowrap\">",
"       thoracic/abdominal/pelvic",
"      </span>",
"      CT scan with and without contrast for the patient with significant ongoing weight loss. An MRI may be ordered as an alternative when IV contrast cannot be administered, assuming there are no contraindications; patients with chronic renal failure should not be given gadolinium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper gastrointestinal endoscopy is indicated for patients with early satiety.",
"     </li>",
"     <li>",
"      Colonoscopy is not indicated in the evaluation of weight loss, as colon cancer does not usually induce weight loss or cachexia unless there is obstruction or extensive metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an underlying cause of weight loss is identified, such as depression, a medical illness, or inability to chew food, it is obviously important to treat the condition. In addition, nutritional repletion should be provided to restore the patient to a target weight, with recognition that weight correction in the older population is less readily accomplished than in younger people.",
"   </p>",
"   <p>",
"    The Council for Nutritional Clinical Strategies in Long-Term Care has developed an evidence-based approach to nutritional surveillance and management for patients in long term care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/72\">",
"     72",
"    </a>",
"    ]. Treatment recommendations are based on common reversible causes of malnutrition, as described by the acronym \"MEALS ON WHEELS\" (",
"    <a class=\"graphic graphic_table graphicRef62358 \" href=\"mobipreview.htm?0/23/380\">",
"     table 2",
"    </a>",
"    ). Likewise, the American Academy of Home Care Physicians has developed guidelines for unintended weight loss in home care patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from studies of acute hospitalization in older patients suggest that up to 71 percent are at nutritional risk or are malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/1\">",
"     1",
"    </a>",
"    ]. One randomized trial found that individualized nutritional management by a dietician (involving one visit during hospitalization and three home visits subsequent to discharge) resulted in improved scores on the Mini Nutritional Assessment and higher albumin levels in the intervention group, compared to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/74\">",
"     74",
"    </a>",
"    ]. Decreased mortality rates at six months were also found (3.8 versus 11.6 percent for intervention and controls respectively), although high study dropout rates and issues with randomization allocation may have impacted this finding. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357960\">",
"    <span class=\"h2\">",
"     Calorie and protein requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calorie needs (the estimated energy requirement, or EER) can be calculated in older adults using the following equations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women: &nbsp; 354.1 &ndash; (6.91 x age [y]) + PAC x (9.36 x weight [kg] + 726 x height [m]).",
"     </li>",
"     <li>",
"      For men: &nbsp; &nbsp; &nbsp; 661.8 - (9.53 x age [y]) + PAC x (15.91 x weight [kg] + 539.6 x height [m]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Physical Activity Coefficient (PAC) is determined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sedentary &nbsp; &nbsp; PAC = 1.0",
"     </li>",
"     <li>",
"      Low activity &nbsp; PAC = 1.12",
"     </li>",
"     <li>",
"      Active &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PAC = 1.27",
"     </li>",
"     <li>",
"      Very active &nbsp; &nbsp;PAC = 1.45",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Protein needs do not appear to change significantly with age, although studies evaluating protein intake in older adults have shown wide variation in optimal protein requirements. A meta-analysis of data from 19 studies of nitrogen balance in older adults found no significant effect of age on the amount of protein required per kilogram of body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Institute of Medicine has determined that the recommended dietary allowance (RDA) for protein for men and women 51 years of age and older is 0.80",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    body",
"    <span class=\"nowrap\">",
"     weight/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Inadequate food intake",
"    </span>",
"   </p>",
"   <p>",
"    If the patient's food intake is inadequate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lift dietary restrictions whenever possible. In one study, undernutrition (average weight loss &gt;1 pound per month, serum albumin &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dl)",
"      </span>",
"      was associated with dietary restrictions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/78\">",
"       78",
"      </a>",
"      ]. Fifty-nine percent of the patients with weight loss and 75.2 percent of those with hypoalbuminemia were on some type of dietary restriction.",
"      <br/>",
"      <br/>",
"      In older, nutritionally high risk adults with diabetes, regular monitoring of blood glucose and adjustment of medication is preferable to dietary restriction or even a \"no concentrated sweets\" prescription. The short-term substitution of a regular diet for a diabetic diet increased calorie consumption and did not cause gross deterioration of glycemic control in a study of chronic care patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Make sure that feeding or shopping assistance is available, if appropriate. In a crossover controlled trial of feeding assistance in nursing home residents at risk of weight loss, those in the intervention group showed a significant increase in daily caloric intake and either maintained or gained weight, whereas those in the control group lost weight. Feeding assistance was resource-intensive and required an average 37 more minutes of staff time per meal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/80\">",
"       80",
"      </a>",
"      ]. Social work support may be important if inadequate finances are contributing to poor intake.",
"     </li>",
"     <li>",
"      Assure that meals and foods meet individual tastes. Suggest offering foods that fit the patient's ethnic or regional preferences.",
"     </li>",
"     <li>",
"      Consider ways to supplement the patient's diet. Increase the nutrient density of food. For example, increase protein content by adding milk powder, whey protein (found in many health food stores), egg whites, or tofu. Increase fat content by adding olive oil (or other \"good fat\") in preparation of sauces, fresh or cooked vegetables, and grains or pasta. If weight does not improve, offer daytime snacks between meals.",
"     </li>",
"     <li>",
"      Give a daily multivitamin and mineral supplement until the cause of inadequate intake is determined.",
"     </li>",
"     <li>",
"      Consider a liquid dietary supplement. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nutritional supplements'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nutritional supplements",
"    </span>",
"   </p>",
"   <p>",
"    A meta-analysis evaluated 55 randomized trials of nutritional supplements containing protein and energy to prevent malnutrition in older, high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/73\">",
"     73",
"    </a>",
"    ]. Studies were generally judged to be of poor quality, due to lack of blinding and intent to treat analysis. The trials evaluated supplements providing between 175 and 1000 additional",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    and between 10 and 36 g",
"    <span class=\"nowrap\">",
"     protein/day.",
"    </span>",
"    Most subjects (45 percent) were hospitalized for stroke; 16 percent were community-based and 10 percent in long-term care facilities.",
"   </p>",
"   <p>",
"    Nutritional supplementation resulted in modest improvement in percentage weight change (weighted mean difference 1.75 percent, 95% CI 1.2 to 2.3), with slightly greater weight increase in patients at home or in long-term care. Overall mortality was reduced in the groups receiving nutritional supplement, compared to control, but there was no mortality impact for patients living at home, and no improvement in functional status. The greatest mortality impact was found in hospitalized undernourished patients who were 75 years or older, and who received supplements with higher calorie content. Complication rates were lower for hospitalized patients who received supplementation, but there was no change in hospital length of stay.",
"   </p>",
"   <p>",
"    In another meta-analysis, there was some evidence that volitional nutrient support (VNS) improved survival among malnourished geriatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/81\">",
"     81",
"    </a>",
"    ]. Findings were significant for low-quality trials; two high quality trials found benefit for VNS in this population, but the difference from control did not reach statistical significance.",
"   </p>",
"   <p>",
"    A randomized crossover trial of amino acid supplements in 41 sarcopenic older adults demonstrated increases in whole-body lean mass at six and 12 months. This study also demonstrated that supplementation led to improved nutrition as reflected by Mini Nutritional Assessment (MNA) scores, improved albumin levels, decreased scores for depression measured by the Geriatric Depression Scale (GDS), and better hand grip strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/82\">",
"     82",
"    </a>",
"    ]. More studies are needed in the sarcopenic geriatric population before amino acid supplementation can be generally recommended in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Appetite stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of appetite stimulants (orexigenics) may be considered, although there are few studies of use of these medications in the older population with weight loss and failure to thrive. There is inadequate information to determine the appropriate use of orexigenics in older adults with cachexia. The complex interplay between inflammation, catabolism, and nutritional substrate in cachexia demands multimodal interventions that address all three elements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Megestrol acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    , a progestational agent, has been shown to yield weight gain in patients with anorexia and cachexia. Megestrol acetate has demonstrated weight gain and improved quality of life for patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    800 mg daily for 12 weeks improved appetite and sense of well-being in a group of nursing home residents. However, weight gain was not found to be significant (&gt;4 lbs) until three months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/86\">",
"     86",
"    </a>",
"    ]. Weight gain was more prominent in residents with elevated cytokine concentrations.",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    should be watched closely for edema and worsening of congestive heart failure. Small studies have also demonstrated impaired function of the corticoadrenal axis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/87\">",
"     87",
"    </a>",
"    ], and increased incidence of deep venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/88\">",
"     88",
"    </a>",
"    ] in patients treated with megestrol. Megestrol may also have adverse effects on muscle. In a randomized trial of exercise training and megestrol in older veterans, subjects who took megestrol had less gain in muscle strength or functional performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dronabinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    has been shown to improve appetite in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/90\">",
"     90",
"    </a>",
"    ]; it was not as effective as megestrol in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/91\">",
"     91",
"    </a>",
"    ]. Dronabinol has not been well-studied in older adults. A limited non-randomized trial showed that dronabinol may be useful for anorexia, weight gain, and behavior problems in patients with advanced Alzheimer disease who were refusing food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    has significant CNS side effects, limiting its use for most older adult populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1520755\">",
"    <span class=\"h3\">",
"     Mirtazapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    , an antidepressant that leads to more weight gain than SSRI antidepressants, is commonly used for management of depression and weight loss in older adults. However, few studies have been specifically performed to evaluate its impact on weight among older adults with weight loss. Two studies in nursing home residents did not show conclusive benefit for mirtazapine over other non-tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OVERNUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Heart, Lung and Blood Institute clinical guidelines define overweight as a BMI of 25 to 29.9 and obesity as a BMI of 30 or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/95\">",
"     95",
"    </a>",
"    ]. For the population as a whole, higher body weights are associated with increase in all-cause mortality, as well as morbidity related to hypertension, dyslipidemia, type 2 diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnea and respiratory problems, and endometrial, breast, prostate, and colon cancers.",
"   </p>",
"   <p>",
"    Several studies suggest that the relationship of overweight or obesity to mortality declines over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the Longitudinal Study of Aging found that a relatively high BMI (30 to 35 for women and 27 to 30 for men) was associated with minimal excess risk for mortality in adults older than 70 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A longitudinal study of over 500,000 adults in the US found a decrease in the association of obesity with cardiovascular disease mortality over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from several other long-term observational studies, including the Cardiovascular Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/98,99\">",
"       98,99",
"      </a>",
"      ], the Medicare Current Beneficiary Surveys [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/100\">",
"       100",
"      </a>",
"      ], and the National Long Term Care Survey [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/101\">",
"       101",
"      </a>",
"      ] have also found that being overweight does not increase mortality risk for people age 65 years and older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, BMI and weight may not be reliable indicators of overweight or obesity in older populations, where normal weight may reflect loss of muscle mass rather than decreased adiposity. A few studies suggest that being overweight as an older adult is associated with increased mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of men 60 to 79 years in the United Kingdom, mortality was not increased for overweight or obese participants as defined by BMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/102\">",
"       102",
"      </a>",
"      ]. However, mortality risk was increased with increasing waist circumference and with BMI, when data were corrected for differences in midarm muscle circumference. These findings suggest that cardiorespiratory fitness and muscle mass may play an important role in the relationship between BMI and mortality.",
"     </li>",
"     <li>",
"      Another report found a U shaped pattern in women &ge;65 years of age, comparing mortality across weight quintiles, with lower mortality for women in the middle 3 quintiles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/103\">",
"       103",
"      </a>",
"      ]. A J-shaped pattern for BMI and mortality was demonstrated in another study of adults, predominantly men, over age 60 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/104\">",
"       104",
"      </a>",
"      ]. In this study, BMI in the overweight range was protective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though the mortality risk of obesity may lessen with age, there are still potential metabolic and functional benefits to weight loss in the obese older adults. Increasing obesity in older adults is associated with new or worsening disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/100\">",
"     100",
"    </a>",
"    ] and weight loss can improve physical function and quality of life for many older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/105\">",
"     105",
"    </a>",
"    ]. Recommendations to lose or not needs to be individualized to the risk profile of particular patients. Those who are experiencing significant adverse effects associated with obesity (such as pain from osteoarthritis or obstructive sleep apnea) should be encouraged to pursue cautious weight loss, but only in the context of regular exercise and appropriate calcium and vitamin D supplementation. Negative outcomes associated with weight loss in overweight older adults include loss of muscle mass and decrease in bone mineral density; both of these may be mitigated with regular exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MICRONUTRIENT DEFICIENCIES IN OLDER ADULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vitamin B12 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of B12 deficiency in older adults ranges between 10 and 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/108\">",
"     108",
"    </a>",
"    ]. Some persons with low normal serum B12 levels may in fact be deficient, with resultant neurologic, psychological, or hematologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/109\">",
"     109",
"    </a>",
"    ]. The diagnosis may need to be made by measurement of methyl malonic acid, which is elevated with B12 deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, a majority of B12 deficiencies were thought to result from intrinsic factor deficiency. It is now known that approximately 15 percent of older adults (&gt;60 years) poorly absorb protein-bound B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/110\">",
"     110",
"    </a>",
"    ]. This is a result of malabsorption of the food-protein-B12 complex in the stomach, related to gastric achlorhydria and often associated with atrophic gastritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/110\">",
"     110",
"    </a>",
"    ]. This may be consequent to current or past H pylori infection.",
"   </p>",
"   <p>",
"    Concern had been raised that folate fortification of foods may mask macrocytic anemia in those with vitamin B12 deficiency. However, a study using NHANES data for older adults in the post-folate fortification years found that those with B12 deficiency and higher folate levels were more likely to be anemic and to have cognitive impairment than patients with normal folate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high prevalence of B12 deficiency and the ease and safety of treatment, some have advocated routinely screening adults over the age of 65 with a serum vitamin B12 assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/112\">",
"     112",
"    </a>",
"    ]. However, this policy has not been endorsed in formal screening guidelines for the geriatric population.",
"   </p>",
"   <p>",
"    Patients with B12 deficiency can generally be treated with oral B12 and may benefit from increasing the intake of B12 in food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/113\">",
"     113",
"    </a>",
"    ]. Because B12 malabsorption is common in older adults, with potentially significant effects of vitamin B12 deficiency on the nervous system, individuals &gt;51 years of age should take supplements containing vitamin B12, or eat fortified food products. It is prudent to advocate a daily intake of 10 to 15 mcg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/114\">",
"     114",
"    </a>",
"    ]. For food cobalamin malabsorption-induced B12 deficiency, ongoing therapy with 1,000 mcg per day of oral crystalline cyanocobalamin may correct serum vitamin B12 levels and yield adequate hematological responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of sun exposure, impaired skin synthesis of previtamin D, and decreased hydroxylation in the kidney with advancing age contribute to marginal vitamin D status in many older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/116\">",
"     116",
"    </a>",
"    ]. In addition, dietary vitamin D intake is often low in older subjects. It has been estimated that approximately one-half of older women consume less than 137 international units",
"    <span class=\"nowrap\">",
"     (units)/day",
"    </span>",
"    of vitamin D from food, and nearly one-quarter consume less than 65",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate vitamin D status has been linked with muscle weakness, functional impairment, depression, and increased risk of falls and fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. An observational study in a large integrated healthcare system found an association between low vitamin D and increased prevalence of diabetes, hypertension, hyperlipidemia, and peripheral vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/121\">",
"     121",
"    </a>",
"    ]. Lower serum 25-hydroxyvitamin D concentrations in older persons have also been associated with a greater risk of future nursing home admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/122\">",
"     122",
"    </a>",
"    ]. Patients with vitamin D insufficiency may also have relative hypocalcemia and high serum parathyroid hormone (PTH) concentrations; this secondary hyperparathyroidism can be attenuated by the administration of vitamin D supplements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/123-125\">",
"     123-125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many older adults will have low levels of serum of 25-hydroxyvitamin D levels (&lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or 50",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Older individuals at higher risk for vitamin D deficiency include those who are institutionalized, homebound, have limited sun exposure, obesity, dark skin, osteoporosis, or malabsorption. Monitoring of serum levels of 25-hydroxyvitamin D (25-OHD) is recommended for those at high risk, with the goal of achieving levels &ge;30",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Testing at three to four months following initiation of vitamin D supplements, if needed, should be done to assure that the target has been achieved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased consumption of dietary sources of vitamin D should be encouraged in all older adults. In 2010, the Institute of Medicine (IOM) released a report on dietary intake requirements for calcium and vitamin D for normal healthy persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/126\">",
"     126",
"    </a>",
"    ]. The Recommended Dietary Allowance (RDA) of vitamin D for adults through age 70 years is 600 IU with the RDA increasing to 800 IU after age 71. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of vitamin D\", section on 'Requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D supplementation with cholecalciferol (vitamin D3) in doses of 600 to 800 mg daily is suggested for individuals with serum 25OHD level in the range of 20 to 30",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Some individuals may need higher doses. Regimens for vitamin D supplementation for those with serum 25OHD levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Inadequate intake of calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium nutrition is strongly influenced by age. The efficiency of calcium absorption from the gastrointestinal tract decreases significantly after age 60 in both sexes. Individuals between 70 and 90 years of age absorb about one third less calcium than do younger adults. Osteoporosis affects more than 10 million people in the United States, and causes more than 1.5 million fractures within that population each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the impact of calcium deficiency on cortical bone loss, the adequate intake (AI) reference value for Ca for those &gt;51 years of age was increased from 800 (1989 RDA) to 1200",
"    <span class=\"nowrap\">",
"     mg/d.",
"    </span>",
"    Food sources of calcium and available calcium supplements are shown in tables (",
"    <a class=\"graphic graphic_table graphicRef63342 \" href=\"mobipreview.htm?24/45/25307\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78814 \" href=\"mobipreview.htm?36/12/37068\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2230186\">",
"    <span class=\"h2\">",
"     Multivitamin supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether multivitamin (MVI) supplementation should be routinely recommended to older adults remains a source of some controversy and confusion. Many older adults use MVI supplements. In the 1999-2000 National Health and Nutrition Examination Survey (NHANES), 35 percent of adults in the United States used multivitamin-multimineral supplements (MVM) and older adults were more likely than younger groups to use them (OR 1.7, 95% CI 1.3-2.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/128\">",
"     128",
"    </a>",
"    ]. In a longitudinal cohort study of predominantly white older women, the use of dietary supplements increased significantly between 1986 and 2004 (from 63 to 85 percent of women reporting use of at least one supplement daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MVM supplementation has been recommended for older adults who are more likely to have compromised nutritional status (such as those in the long term care setting), to help achieve recommended intakes of certain micronutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/130\">",
"     130",
"    </a>",
"    ]. Current evidence, however, provides only weak support for this practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 263 older adults attending senior centers, nutrient intake was estimated from dietary recalls and reported use of MVM supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/131\">",
"       131",
"      </a>",
"      ]. Subjects who reported taking MVM were calculated to have improved intakes of vitamins E, D, B6,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      , and calcium, but were likely to exceed the Tolerable Upper Limit for niacin, folic acid, and vitamin A.",
"     </li>",
"     <li>",
"      In a study of 4384 adults 51 years of age and older, supplements improved the nutrient intake of older adults. After accounting for the contribution of supplements, 80 percent or more of users met the estimated average requirement (EAR) for vitamins A, B6, B12, C, and E as well as for folate, iron, and zinc, but not for magnesium. However, some supplement users, particularly men, exceeded Tolerable Upper Intake Levels for iron and zinc and a small percentage of women exceeded the Tolerable Upper Intake Level for vitamin A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A few studies have suggested that MVM might reduce the incidence of infections, and upper respiratory tract infections in particular. In a systematic review of eight randomized trials of multivitamins and mineral supplements primarily involving older adults, three studies found that MVM reduced the number of days spent with infection by 17.5 (95% CI 11-24) but analysis of four studies showed no impact on the infection rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/133\">",
"       133",
"      </a>",
"      ]. In an 18-month randomized trial involving 763 institutionalized older adults from 21 long-term care facilities, there was no statistically significant difference in the rate of infections in the supplement and placebo groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort study of 38,772 older women followed for over 20 years with a mean age of 61.6 at baseline, supplementation with daily multivitamins was associated with a small increase in total mortality (HR 1.06, 95% CI 1.02-1.10) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/129\">",
"       129",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, routine supplementation with multivitamins and minerals is not indicated to reduce infections in frail seniors and is likely not beneficial unless it is clear that the older adult is not meeting his or her micronutrient needs due to low overall intake. The 2006 NIH Consensus Conference on the use of MVM found evidence insufficient to recommend for or against the use of MVMs to prevent chronic disease for the US population in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/12/31946/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=see_link\">",
"       \"Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The involuntary loss of more than 5 to 10 percent of an older person's usual weight during one year is an important clinical sign associated with increased risk for mortality. Weight loss should thus be met with concern and prompt a search for the cause. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Involuntary weight loss is generally related to one or a combination of four conditions: inadequate dietary intake, appetite loss (anorexia), muscle atrophy (sarcopenia), or inflammatory effects of disease (cachexia). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inadequate dietary intake may relate to social, psychological, medical, and physiologic issues. Depression is the most prevalent associated condition in several studies, with cancer as the second most common cause. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Inadequate dietary intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pro-inflammatory cytokines are common in older adults and are particularly elevated in patients with cachexia. Sarcopenia is often related to a reduction in testosterone and estrogen and increase in insulin resistance. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cachexia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Sarcopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of weight loss should include serial weight measurements, dietary or appetite assessment, history, physical examination, and screening laboratory studies (CBC, chemistry profile, thyroid studies). Additional studies should be based on findings of the initial evaluation and may include upper GI endoscopy for patients with early satiety or",
"      <span class=\"nowrap\">",
"       thoracic/abdominal/pelvic",
"      </span>",
"      CT scan for patients with unexplained ongoing weight loss. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Evaluation of weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should be directed at the underlying cause (ie, treatment for depression) as well as dietary modification. Nutritional restrictions should be lifted; patients with diabetes may do well with a regular diet and adequate monitoring. High-calorie foods should be provided.",
"      <br/>",
"      <br/>",
"      We suggest providing oral nutritional supplementation for patients who do not regain weight with adjustments in meal preparation and diet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating patients with appetite stimulants (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      ) due to marginal benefit and potential side effects (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nutritional supplements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Appetite stimulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality risk in people over age 70 is not significantly impacted by an elevated BMI in the 25.0 to 29.9 range. Advice regarding weight loss for the overweight older person should be tailored to the individual, assessing the impact of excess weight on their quality of life, and should include the need for regular exercise. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Overnutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin B12 deficiency affects about 15 percent of people &gt;60 years in the US and most commonly relates to malabsorption of food-protein-B12 complexes. Oral B12 supplements, 1000 mcg daily, can usually correct B12 deficiency in the older adult. Daily intake of B12 10 to 15 mcg, by supplement or fortified products in the diet, is recommended for individuals &gt;50 years. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Vitamin B12 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D deficiency is also common in the older population. Vitamin D supplements or fortified foods should supply 600 to 800 IU of vitamin D per day for older adults. Additionally, 1200",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      of elemental calcium should be provided daily. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Vitamin D deficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Inadequate intake of calcium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/1\">",
"      de Luis D, Lopez Guzman A, Nutrition Group of Society of Cstilla-Leon (Endocrinology, Diabetes and Nutrition). Nutritional status of adult patients admitted to internal medicine departments in public hospitals in Castilla y Leon, Spain - A multi-center study. Eur J Intern Med 2006; 17:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/2\">",
"      Wallace JI, Schwartz RS, LaCroix AZ, et al. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc 1995; 43:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/3\">",
"      White JV, Guenter P, Jensen G, et al. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr 2012; 36:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/4\">",
"      Wannamethee SG, Shaper AG, Lennon L. Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. Arch Intern Med 2005; 165:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/5\">",
"      Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003; 138:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/6\">",
"      Newman AB, Yanez D, Harris T, et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001; 49:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/7\">",
"      Locher JL, Roth DL, Ritchie CS, et al. Body mass index, weight loss, and mortality in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2007; 62:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/8\">",
"      Bales CW, Buhr G. Is obesity bad for older persons? A systematic review of the pros and cons of weight reduction in later life. J Am Med Dir Assoc 2008; 9:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/9\">",
"      Shea MK, Houston DK, Nicklas BJ, et al. The effect of randomization to weight loss on total mortality in older overweight and obese adults: the ADAPT Study. J Gerontol A Biol Sci Med Sci 2010; 65:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/10\">",
"      Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/11\">",
"      Zawada ET Jr. Malnutrition in the elderly. Is it simply a matter of not eating enough? Postgrad Med 1996; 100:207.",
"     </a>",
"    </li>",
"    <li>",
"     Health Care Financing Administration. Long Term Care Facility Resident Assessment (RAI) User's Manual, Minimum Data Set, Version 2, Eliot Press, Natick, MA 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/13\">",
"      Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/14\">",
"      Skipper A, Ferguson M, Thompson K, et al. Nutrition screening tools: an analysis of the evidence. JPEN J Parenter Enteral Nutr 2012; 36:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/15\">",
"      Wilson MM, Thomas DR, Rubenstein LZ, et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/16\">",
"      Keller HH, Goy R, Kane SL. Validity and reliability of SCREEN II (Seniors in the community: risk evaluation for eating and nutrition, Version II). Eur J Clin Nutr 2005; 59:1149.",
"     </a>",
"    </li>",
"    <li>",
"     Tools can be purchased from Professor Heather Keller, RD, PhD. Contact hkeller@uoguelph.ca.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/18\">",
"      Stratton RJ, King CL, Stroud MA, et al. 'Malnutrition Universal Screening Tool' predicts mortality and length of hospital stay in acutely ill elderly. Br J Nutr 2006; 95:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/19\">",
"      Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition 1999; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     MNA Mini nutritional assessment. Available at: www.mna-elderly.com (Accessed on November 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/21\">",
"      Charlton KE, Kolbe-Alexander TL, Nel JH. The MNA, but not the DETERMINE, screening tool is a valid indicator of nutritional status in elderly Africans. Nutrition 2007; 23:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/22\">",
"      Sieber CC. Nutritional screening tools--How does the MNA compare? Proceedings of the session held in Chicago May 2-3, 2006 (15 Years of Mini Nutritional Assessment). J Nutr Health Aging 2006; 10:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/23\">",
"      Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 1999; 15:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/24\">",
"      Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging 2009; 13:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/25\">",
"      Kaiser MJ, Bauer JM, R&auml;msch C, et al. Frequency of malnutrition in older adults: a multinational perspective using the mini nutritional assessment. J Am Geriatr Soc 2010; 58:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/26\">",
"      Shen HC, Chen HF, Peng LN, et al. Impact of nutritional status on long-term functional outcomes of post-acute stroke patients in Taiwan. Arch Gerontol Geriatr 2011; 53:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/27\">",
"      Baumeister SE, Fischer B, D&ouml;ring A, et al. The Geriatric Nutritional Risk Index predicts increased healthcare costs and hospitalization in a cohort of community-dwelling older adults: results from the MONICA/KORA Augsburg cohort study, 1994-2005. Nutrition 2011; 27:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/28\">",
"      Leandro-Merhi VA, de Aquino JL, Sales Chagas JF. Nutrition status and risk factors associated with length of hospital stay for surgical patients. JPEN J Parenter Enteral Nutr 2011; 35:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/29\">",
"      Mudge AM, Ross LJ, Young AM, et al. Helping understand nutritional gaps in the elderly (HUNGER): a prospective study of patient factors associated with inadequate nutritional intake in older medical inpatients. Clin Nutr 2011; 30:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/30\">",
"      Roberts SB. Regulation of energy intake in relation to metabolic state and nutritional status. Eur J Clin Nutr 2000; 54 Suppl 3:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/31\">",
"      Winkels RM, Jolink-Stoppelenburg A, de Graaf K, et al. Energy intake compensation after 3 weeks of restricted energy intake in young and elderly men. J Am Med Dir Assoc 2011; 12:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/32\">",
"      de Castro JM, Brewer EM. The amount eaten in meals by humans is a power function of the number of people present. Physiol Behav 1992; 51:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/33\">",
"      Locher JL, Robinson CO, Roth DL, et al. The effect of the presence of others on caloric intake in homebound older adults. J Gerontol A Biol Sci Med Sci 2005; 60:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/34\">",
"      Wilson MM, Vaswani S, Liu D, et al. Prevalence and causes of undernutrition in medical outpatients. Am J Med 1998; 104:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/35\">",
"      Thompson MP, Morris LK. Unexplained weight loss in the ambulatory elderly. J Am Geriatr Soc 1991; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/36\">",
"      Rabinovitz M, Pitlik SD, Leifer M, et al. Unintentional weight loss. A retrospective analysis of 154 cases. Arch Intern Med 1986; 146:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/37\">",
"      Achem SR, Devault KR. Dysphagia in aging. J Clin Gastroenterol 2005; 39:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/38\">",
"      Keller HH. Malnutrition in institutionalized elderly: how and why? J Am Geriatr Soc 1993; 41:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/39\">",
"      Mann G, Hankey GJ, Cameron D. Swallowing disorders following acute stroke: prevalence and diagnostic accuracy. Cerebrovasc Dis 2000; 10:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/40\">",
"      Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/41\">",
"      Gu&eacute;rin O, Andrieu S, Schneider SM, et al. Characteristics of Alzheimer's disease patients with a rapid weight loss during a six-year follow-up. Clin Nutr 2009; 28:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/42\">",
"      Ritchie CS, Joshipura K, Silliman RA, et al. Oral health problems and significant weight loss among community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2000; 55:M366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/43\">",
"      Rolls BJ. Do chemosensory changes influence food intake in the elderly? Physiol Behav 1999; 66:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/44\">",
"      Horowitz M, Maddern GJ, Chatterton BE, et al. Changes in gastric emptying rates with age. Clin Sci (Lond) 1984; 67:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/45\">",
"      Parker BA, Chapman IM. Food intake and ageing--the role of the gut. Mech Ageing Dev 2004; 125:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/46\">",
"      Roberts SB. A review of age-related changes in energy regulation and suggested mechanisms. Mech Ageing Dev 2000; 116:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/47\">",
"      Morley JE. Decreased food intake with aging. J Gerontol A Biol Sci Med Sci 2001; 56 Spec No 2:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/48\">",
"      Engel JH, Siewerdt F, Jackson R, et al. Hardiness, depression, and emotional well-being and their association with appetite in older adults. J Am Geriatr Soc 2011; 59:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/49\">",
"      Evans WJ, Morley JE, Argil&eacute;s J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/50\">",
"      Martinez M, Arnalich F, Hernanz A. Alterations of anorectic cytokine levels from plasma and cerebrospinal fluid in idiopathic senile anorexia. Mech Ageing Dev 1993; 72:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/51\">",
"      Oldenburg HS, Rogy MA, Lazarus DD, et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 1993; 23:1889.",
"     </a>",
"    </li>",
"    <li>",
"     Aggarwal BB, Puri RK. Human Cytokines: Their Role in Disease and Therapy, Blackwell Science, Cambridge, MA 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/53\">",
"      Roubenoff R, Harris TB, Abad LW, et al. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998; 53:M20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/54\">",
"      Roubenoff R. Origins and clinical relevance of sarcopenia. Can J Appl Physiol 2001; 26:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/55\">",
"      Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/56\">",
"      Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med 2011; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/57\">",
"      Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/58\">",
"      Muscaritoli M, Anker SD, Argil&eacute;s J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) \"cachexia-anorexia in chronic wasting diseases\" and \"nutrition in geriatrics\". Clin Nutr 2010; 29:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/59\">",
"      Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 2006; 54:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/60\">",
"      Lindle RS, Metter EJ, Lynch NA, et al. Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr. J Appl Physiol 1997; 83:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/61\">",
"      Joseph C, Kenny AM, Taxel P, et al. Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med 2005; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/62\">",
"      Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr 2004; 80:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/63\">",
"      Kenny AM, Dawson L, Kleppinger A, et al. Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy. J Gerontol A Biol Sci Med Sci 2003; 58:M436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/64\">",
"      Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/65\">",
"      Rasmussen BB, Fujita S, Wolfe RR, et al. Insulin resistance of muscle protein metabolism in aging. FASEB J 2006; 20:768.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Healthy People 2010, 2nd ed. Government Printing Office; US Department of Health and Human Services, Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/67\">",
"      Rantanen T, Era P, Heikkinen E. Physical activity and the changes in maximal isometric strength in men and women from the age of 75 to 80 years. J Am Geriatr Soc 1997; 45:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/68\">",
"      Kyle UG, Morabia A, Schutz Y, Pichard C. Sedentarism affects body fat mass index and fat-free mass index in adults aged 18 to 98 years. Nutrition 2004; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/69\">",
"      Garry PJ, Goodwin JS, Hunt WC, et al. Nutritional status in a healthy elderly population: dietary and supplemental intakes. Am J Clin Nutr 1982; 36:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/70\">",
"      Robinson SM, Jameson KA, Batelaan SF, et al. Diet and its relationship with grip strength in community-dwelling older men and women: the Hertfordshire cohort study. J Am Geriatr Soc 2008; 56:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/71\">",
"      Hern&aacute;ndez JL, Riancho JA, Matorras P, Gonz&aacute;lez-Mac&iacute;as J. Clinical evaluation for cancer in patients with involuntary weight loss without specific symptoms. Am J Med 2003; 114:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/72\">",
"      Thomas DR, Ashmen W, Morley JE, Evans WJ. Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci 2000; 55:M725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/73\">",
"      Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older people. Ann Intern Med 2006; 144:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/74\">",
"      Feldblum I, German L, Castel H, et al. Individualized nutritional intervention during and after hospitalization: the nutrition intervention study clinical trial. J Am Geriatr Soc 2011; 59:10.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Institute of Medicine and National Acadamies Press 2005. Available at: file://www.nal.usda.gov/fnic/DRI//DRI_Energy/energy_full_report.pdf (Accessed on August 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/76\">",
"      Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults. Am J Clin Nutr 2003; 77:109.",
"     </a>",
"    </li>",
"    <li>",
"     Panel on Macronutrients, Panel on the Definition of Dietary Fiber, Subcommittee on Upper Reference Levels of Nutrients, et al. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), The National Academies Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/78\">",
"      Buckler DA, Kelber ST, Goodwin JS. The use of dietary restrictions in malnourished nursing home patients. J Am Geriatr Soc 1994; 42:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/79\">",
"      Coulston AM, Mandelbaum D, Reaven GM. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1990; 51:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/80\">",
"      Simmons SF, Keeler E, Zhuo X, et al. Prevention of unintentional weight loss in nursing home residents: a controlled trial of feeding assistance. J Am Geriatr Soc 2008; 56:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/81\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/82\">",
"      Rondanelli M, Opizzi A, Antoniello N, et al. Effect of essential amino acid supplementation on quality of life, amino acid profile and strength in institutionalized elderly patients. Clin Nutr 2011; 30:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/83\">",
"      Solerte SB, Gazzaruso C, Bonacasa R, et al. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. Am J Cardiol 2008; 101:69E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/84\">",
"      Pascual L&oacute;pez A, Roqu&eacute; i Figuls M, Urr&uacute;tia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/85\">",
"      Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005; :CD004310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/86\">",
"      Yeh SS, Wu SY, Lee TP, et al. Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. J Am Geriatr Soc 2000; 48:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/87\">",
"      Reuben DB, Hirsch SH, Zhou K, Greendale GA. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial. J Am Geriatr Soc 2005; 53:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/88\">",
"      Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 2003; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/89\">",
"      Sullivan DH, Roberson PK, Smith ES, et al. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc 2007; 55:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/90\">",
"      Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/91\">",
"      Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/92\">",
"      Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/93\">",
"      Mihara IQ, McCombs JS, Williams BR. The impact of mirtazapine compared with non-TCA antidepressants on weight change in nursing facility residents. Consult Pharm 2005; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/94\">",
"      Goldberg RJ. Weight change in depressed nursing home patients on mirtazapine. J Am Geriatr Soc 2002; 50:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/95\">",
"      Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/96\">",
"      Allison DB, Gallagher D, Heo M, et al. Body mass index and all-cause mortality among people age 70 and over: the Longitudinal Study of Aging. Int J Obes Relat Metab Disord 1997; 21:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/97\">",
"      Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/98\">",
"      Diehr P, Bild DE, Harris TB, et al. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health 1998; 88:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/99\">",
"      Diehr P, O'Meara ES, Fitzpatrick A, et al. Weight, mortality, years of healthy life, and active life expectancy in older adults. J Am Geriatr Soc 2008; 56:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/100\">",
"      Wee CC, Huskey KW, Ngo LH, et al. Obesity, race, and risk for death or functional decline among Medicare beneficiaries: a cohort study. Ann Intern Med 2011; 154:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/101\">",
"      Kulminski AM, Arbeev KG, Kulminskaya IV, et al. Body mass index and nine-year mortality in disabled and nondisabled older U.S. individuals. J Am Geriatr Soc 2008; 56:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/102\">",
"      Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Decreased muscle mass and increased central adiposity are independently related to mortality in older men. Am J Clin Nutr 2007; 86:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/103\">",
"      Dolan CM, Kraemer H, Browner W, et al. Associations between body composition, anthropometry, and mortality in women aged 65 years and older. Am J Public Health 2007; 97:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/104\">",
"      Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 2007; 298:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/105\">",
"      Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/106\">",
"      Villareal DT, Banks M, Sinacore DR, et al. Effect of weight loss and exercise on frailty in obese older adults. Arch Intern Med 2006; 166:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/107\">",
"      Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006; 166:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/108\">",
"      Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992; 40:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/109\">",
"      Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 1990; 34:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/110\">",
"      Andr&egrave;s E, Affenberger S, Vinzio S, et al. Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment. Am J Med 2005; 118:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/111\">",
"      Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007; 85:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/112\">",
"      Stabler SP. Screening the older population for cobalamin (vitamin B12) deficiency. J Am Geriatr Soc 1995; 43:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/113\">",
"      Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998; 92:1191.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board, Institute of Medicine. Vitamin B12. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Vitamin B-12, Pantothenic Acid, Biotin, and Choline, National Academy Press, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/115\">",
"      Andr&egrave;s E, Kaltenbach G, Noblet-Dick M, et al. Hematological response to short-term oral cyanocobalamin therapy for the treatment of cobalamin deficiencies in elderly patients. J Nutr Health Aging 2006; 10:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/116\">",
"      Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet 1989; 2:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/117\">",
"      MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/118\">",
"      Milaneschi Y, Shardell M, Corsi AM, et al. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endocrinol Metab 2010; 95:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/119\">",
"      Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004; 291:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/120\">",
"      Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 2005; 16:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/121\">",
"      Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/122\">",
"      Visser M, Deeg DJ, Puts MT, et al. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006; 84:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/123\">",
"      Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/124\">",
"      Need AG, O'Loughlin PD, Morris HA, et al. The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center. J Clin Endocrinol Metab 2004; 89:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/125\">",
"      Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135:317.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     America's bone health: the state of osteoporosis and low bone mass in our nation, National Osteoporosis Foundation, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/128\">",
"      Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004; 160:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/129\">",
"      Mursu J, Robien K, Harnack LJ, et al. Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. Arch Intern Med 2011; 171:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/130\">",
"      Johnson KA, Bernard MA, Funderburg K. Vitamin nutrition in older adults. Clin Geriatr Med 2002; 18:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/131\">",
"      Weeden A, Remig V, Holcomb CA, et al. Vitamin and mineral supplements have a nutritionally significant impact on micronutrient intakes of older adults attending senior centers. J Nutr Elder 2010; 29:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/132\">",
"      Sebastian RS, Cleveland LE, Goldman JD, Moshfegh AJ. Older adults who use vitamin/mineral supplements differ from nonusers in nutrient intake adequacy and dietary attitudes. J Am Diet Assoc 2007; 107:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/133\">",
"      El-Kadiki A, Sutton AJ. Role of multivitamins and mineral supplements in preventing infections in elderly people: systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 330:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/134\">",
"      Liu BA, McGeer A, McArthur MA, et al. Effect of multivitamin and mineral supplementation on episodes of infection in nursing home residents: a randomized, placebo-controlled study. J Am Geriatr Soc 2007; 55:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/12/31946/abstract/135\">",
"      NIH State-of-the-Science Panel. National Institutes of Health State-of-the-science conference statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 2006; 145:364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3016 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-A00CD60D9C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31946=[""].join("\n");
var outline_f31_12_31946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING FOR NUTRITIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Screening tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UNDERNUTRITION SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inadequate dietary intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Social factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Medical and psychiatric factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Physiologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anorexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cachexia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sarcopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION OF WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Subsequent evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3357960\">",
"      Calorie and protein requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Inadequate food intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nutritional supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Appetite stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Megestrol acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dronabinol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1520755\">",
"      - Mirtazapine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OVERNUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MICRONUTRIENT DEFICIENCIES IN OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vitamin B12 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Inadequate intake of calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2230186\">",
"      Multivitamin supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3016\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3016|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/4/36943\" title=\"figure 1\">",
"      SNAQ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/35/5685\" title=\"figure 2\">",
"      Mini nutritional assesment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3016|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/10/23724\" title=\"table 1\">",
"      Geriatric weight chart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/23/380\" title=\"table 2\">",
"      Wt loss elder MealsOnWheels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/45/25307\" title=\"table 3\">",
"      Foods with calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/12/37068\" title=\"table 4\">",
"      Calcium content of supplements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=related_link\">",
"      Approach to the patient with weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/40/23175?source=related_link\">",
"      Dietary and nutritional assessment in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/18/38186?source=related_link\">",
"      Geriatric health maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_12_31947="Genetic testing DMD BMD";
var content_f31_12_31947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular genetic testing used in the dystrophinopathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Test method",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Mutations detected",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Mutation detection frequency in males by phenotype and test method",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       DMD",
"      </td>",
"      <td class=\"subtitle2\">",
"       BMD",
"      </td>",
"      <td class=\"subtitle2\">",
"       XLDCM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Deletion/duplication analysis",
"      </td>",
"      <td>",
"       Deletion of one or more exons of",
"       <em>",
"        DMD",
"       </em>",
"       gene",
"      </td>",
"      <td>",
"       &sim; 65 percent",
"      </td>",
"      <td>",
"       &sim; 85 percent",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Duplication of one or more exons of",
"       <em>",
"        DMD",
"       </em>",
"      </td>",
"      <td>",
"       &sim; 7-10 percent",
"      </td>",
"      <td>",
"       &sim; 6-10 percent",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutation scanning and/or sequence analysis",
"      </td>",
"      <td>",
"       Small insertions/deletions/point mutations/splicing mutations of",
"       <em>",
"        DMD",
"       </em>",
"       gene",
"      </td>",
"      <td>",
"       &sim; 25-30 percent",
"      </td>",
"      <td>",
"       &sim; 5-10 percent",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Darras, BT, Korf, BR, Urion, DK. Dystrophinopathies, September 2000 [Updated March 21, 2008]. GeneReviews at GeneTests: Medical Genetics Information Resource. Copyright &copy; University of Washington, Seattle, 1997-2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31947=[""].join("\n");
var outline_f31_12_31947=null;
var title_f31_12_31948="Differential diagnosis of thromboangiitis obliterans";
var content_f31_12_31948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of thromboangiitis obliterans",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lower extremity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atheroembolism/microthromboembolism (blue toe syndrome, trash foot)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypercoagulability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polycythemia vera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Essential thrombocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antiphospholipid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasculitis/collagen vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polyarteritis nodosa (or other small to medium-sized vessel vasculitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonatherosclerotic vascular disease (adventitial cystic disease, popliteal entrapment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frostbite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ergot poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cannabis arteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Upper extremity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral artery disease (arteriosclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Atheroembolism/thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arterial thoracic outlet syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subclavian aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothenar hammer syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasculitis/collagen vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Scleroderma/CREST",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polyarteritis nodosa and similar forms of vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cocaine or amphetamine vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Prothrombotic states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antiphospholipid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pernio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diseases related to vibratory tools",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ergot poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frostbite",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31948=[""].join("\n");
var outline_f31_12_31948=null;
var title_f31_12_31949="Severity restrictive dz";
var content_f31_12_31949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interpretation of office spirometry: Restrictive pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spirometry interpretation flow chart for the detection of a restrictive ventilatory defect.",
"    <div class=\"footnotes\">",
"     * The fifth percentile lower limit of normal (LLN), as calculated by most spirometers, should be used to detect airway obstruction, rather than the absolute value of the FEV1/FVC ratio.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31949=[""].join("\n");
var outline_f31_12_31949=null;
var title_f31_12_31950="Value of lipid markers";
var content_f31_12_31950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Predictive value of serum markers for coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 528px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows hazard ratios for future cardiac events in initially healthy women comparing extreme quintiles for individual prognostic variables (red) and for lipid ratios (blue) and adjusted for age, blood pressure, body mass index, diabetes, and current smoking status. The hazard ratios compare those in the highest quintile of the prognostic variable with those in the lowest quintile or, for the hazard ratios marked with an asterisk (*), the lowest quintile with the highest quintile. Black bars represent 95% confidence intervals.",
"    <div class=\"footnotes\">",
"     Apo: apolipoprotein; CRP: C-reactive protein; LDL: low density lipoprotein; HDL: high density lipoprotein.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ridker, PM, Rifai, N, Cook, NR, et al. JAMA 2005; 294:326.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31950=[""].join("\n");
var outline_f31_12_31950=null;
var title_f31_12_31951="Unequal crossing over";
var content_f31_12_31951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molecular mechanism of unequal crossing over",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A common mechanism of interstitial deletions is unequal crossing over in meiosis I. When highly homologous repeats (\"Repeat\") flank a DNA segment (\"Gene\"), two non-sister chromatids may recombine at an incorrect location due to inappropriate alignment. Thus, one of the chromatids (labeled \"A\") acquires a duplication of the intervening sequence, while the corresponding segment is deleted on the other chromatid and only one repeat remains (labeled \"B\").",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_12_31951=[""].join("\n");
var outline_f31_12_31951=null;
